<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="cncr34561" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Cancer</journal-id><journal-id journal-id-type="pmc-domain-id">379</journal-id><journal-id journal-id-type="pmc-domain">blackwellopen</journal-id><journal-id journal-id-type="publisher-id">CNCR</journal-id><journal-title-group><journal-title>Cancer</journal-title></journal-title-group><issn pub-type="ppub">0008-543X</issn><issn pub-type="epub">1097-0142</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Wiley Open Access Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10099796</article-id><article-id pub-id-type="pmcid-ver">PMC10099796.1</article-id><article-id pub-id-type="pmcaid">10099796</article-id><article-id pub-id-type="pmcaiid">10099796</article-id><article-id pub-id-type="pmid">36444554</article-id><article-id pub-id-type="doi">10.1002/cncr.34561</article-id><article-id pub-id-type="publisher-id">CNCR34561</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Articles</subject><subj-group subj-group-type="heading"><subject>Discipline</subject><subj-group subj-group-type="heading"><subject>Epidemiology</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Risk of subsequent primary lymphoma in a cohort of 69,460 five&#8208;year survivors of childhood and adolescent cancer in Europe: The PanCareSurFup study</article-title><alt-title alt-title-type="right-running-head">Lymphoma in childhood cancer survivors</alt-title><alt-title alt-title-type="left-running-head">Dudley et al.</alt-title></title-group><contrib-group><contrib id="cncr34561-cr-0001" contrib-type="author"><name name-style="western"><surname>Dudley</surname><given-names initials="IM">Isabelle M.</given-names></name><degrees>MD</degrees><xref rid="cncr34561-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cncr34561-cr-0002" contrib-type="author"><name name-style="western"><surname>Sunguc</surname><given-names initials="C">Ceren</given-names></name><degrees>MSc</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7831-960X</contrib-id><xref rid="cncr34561-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cncr34561-cr-0003" contrib-type="author"><name name-style="western"><surname>Heymer</surname><given-names initials="EJ">Emma J.</given-names></name><degrees>MSc</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5115-0293</contrib-id><xref rid="cncr34561-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cncr34561-cr-0004" contrib-type="author"><name name-style="western"><surname>Winter</surname><given-names initials="DL">David L.</given-names></name><degrees>HNC</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1597-4081</contrib-id><xref rid="cncr34561-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cncr34561-cr-0005" contrib-type="author"><name name-style="western"><surname>Teepen</surname><given-names initials="JC">Jop C.</given-names></name><degrees>PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2647-2677</contrib-id><xref rid="cncr34561-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="cncr34561-cr-0006" contrib-type="author"><name name-style="western"><surname>Belle</surname><given-names initials="FN">Fabi&#235;n N.</given-names></name><degrees>PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0037-4817</contrib-id><xref rid="cncr34561-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="cncr34561-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="cncr34561-cr-0007" contrib-type="author"><name name-style="western"><surname>B&#225;rdi</surname><given-names initials="E">Edit</given-names></name><degrees>MD, PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7424-6255</contrib-id><xref rid="cncr34561-aff-0005" ref-type="aff">
<sup>5</sup>
</xref><xref rid="cncr34561-aff-0006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib id="cncr34561-cr-0008" contrib-type="author"><name name-style="western"><surname>Bagnasco</surname><given-names initials="F">Francesca</given-names></name><degrees>PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1601-9518</contrib-id><xref rid="cncr34561-aff-0007" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib id="cncr34561-cr-0009" contrib-type="author"><name name-style="western"><surname>Gudmundsdottir</surname><given-names initials="T">Thorgerdur</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6396-1018</contrib-id><xref rid="cncr34561-aff-0008" ref-type="aff">
<sup>8</sup>
</xref><xref rid="cncr34561-aff-0009" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib id="cncr34561-cr-0010" contrib-type="author"><name name-style="western"><surname>Skinner</surname><given-names initials="R">Roderick</given-names></name><degrees>MD, PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1162-675X</contrib-id><xref rid="cncr34561-aff-0010" ref-type="aff">
<sup>10</sup>
</xref><xref rid="cncr34561-aff-0011" ref-type="aff">
<sup>11</sup>
</xref></contrib><contrib id="cncr34561-cr-0011" contrib-type="author"><name name-style="western"><surname>Michel</surname><given-names initials="G">Gisela</given-names></name><degrees>PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9589-0928</contrib-id><xref rid="cncr34561-aff-0012" ref-type="aff">
<sup>12</sup>
</xref></contrib><contrib id="cncr34561-cr-0012" contrib-type="author"><name name-style="western"><surname>Byrne</surname><given-names initials="J">Julianne</given-names></name><degrees>PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1070-3004</contrib-id><xref rid="cncr34561-aff-0013" ref-type="aff">
<sup>13</sup>
</xref></contrib><contrib id="cncr34561-cr-0013" contrib-type="author"><name name-style="western"><surname>&#216;fstaas</surname><given-names initials="H">Hilde</given-names></name><degrees>PhD</degrees><xref rid="cncr34561-aff-0014" ref-type="aff">
<sup>14</sup>
</xref></contrib><contrib id="cncr34561-cr-0014" contrib-type="author"><name name-style="western"><surname>Jankovic</surname><given-names initials="M">Momcilo</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9773-0576</contrib-id><xref rid="cncr34561-aff-0015" ref-type="aff">
<sup>15</sup>
</xref></contrib><contrib id="cncr34561-cr-0015" contrib-type="author"><name name-style="western"><surname>Mazi&#263;</surname><given-names initials="M&#x10C;">Maja &#268;esen</given-names></name><degrees>MD, PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2434-8960</contrib-id><xref rid="cncr34561-aff-0016" ref-type="aff">
<sup>16</sup>
</xref></contrib><contrib id="cncr34561-cr-0016" contrib-type="author"><name name-style="western"><surname>Mader</surname><given-names initials="L">Luzius</given-names></name><degrees>PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5613-4356</contrib-id><xref rid="cncr34561-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="cncr34561-cr-0017" contrib-type="author"><name name-style="western"><surname>Loonen</surname><given-names initials="J">Jaqueline</given-names></name><degrees>MD, PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9963-8367</contrib-id><xref rid="cncr34561-aff-0017" ref-type="aff">
<sup>17</sup>
</xref></contrib><contrib id="cncr34561-cr-0018" contrib-type="author"><name name-style="western"><surname>Garwicz</surname><given-names initials="S">Stanislaw</given-names></name><degrees>MD</degrees><xref rid="cncr34561-aff-0018" ref-type="aff">
<sup>18</sup>
</xref></contrib><contrib id="cncr34561-cr-0019" contrib-type="author"><name name-style="western"><surname>Wiebe</surname><given-names initials="T">Thomas</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7567-9076</contrib-id><xref rid="cncr34561-aff-0018" ref-type="aff">
<sup>18</sup>
</xref></contrib><contrib id="cncr34561-cr-0020" contrib-type="author"><name name-style="western"><surname>Alessi</surname><given-names initials="D">Daniela</given-names></name><degrees>PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3746-3346</contrib-id><xref rid="cncr34561-aff-0019" ref-type="aff">
<sup>19</sup>
</xref><xref rid="cncr34561-aff-0020" ref-type="aff">
<sup>20</sup>
</xref></contrib><contrib id="cncr34561-cr-0021" contrib-type="author"><name name-style="western"><surname>Allodji</surname><given-names initials="RS">Rodrigue S.</given-names></name><degrees>PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1895-8415</contrib-id><xref rid="cncr34561-aff-0021" ref-type="aff">
<sup>21</sup>
</xref></contrib><contrib id="cncr34561-cr-0022" contrib-type="author"><name name-style="western"><surname>Haddy</surname><given-names initials="N">Nadia</given-names></name><degrees>PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9316-8280</contrib-id><xref rid="cncr34561-aff-0021" ref-type="aff">
<sup>21</sup>
</xref></contrib><contrib id="cncr34561-cr-0023" contrib-type="author"><name name-style="western"><surname>Grabow</surname><given-names initials="D">Desiree</given-names></name><degrees>PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4853-3303</contrib-id><xref rid="cncr34561-aff-0022" ref-type="aff">
<sup>22</sup>
</xref></contrib><contrib id="cncr34561-cr-0024" contrib-type="author"><name name-style="western"><surname>Kaatsch</surname><given-names initials="P">Peter</given-names></name><degrees>PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8565-0832</contrib-id><xref rid="cncr34561-aff-0022" ref-type="aff">
<sup>22</sup>
</xref></contrib><contrib id="cncr34561-cr-0025" contrib-type="author"><name name-style="western"><surname>Kaiser</surname><given-names initials="M">Melanie</given-names></name><degrees>PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3362-2530</contrib-id><xref rid="cncr34561-aff-0022" ref-type="aff">
<sup>22</sup>
</xref></contrib><contrib id="cncr34561-cr-0026" contrib-type="author"><name name-style="western"><surname>Maule</surname><given-names initials="MM">Milena M.</given-names></name><degrees>PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2142-1288</contrib-id><xref rid="cncr34561-aff-0019" ref-type="aff">
<sup>19</sup>
</xref><xref rid="cncr34561-aff-0020" ref-type="aff">
<sup>20</sup>
</xref></contrib><contrib id="cncr34561-cr-0027" contrib-type="author"><name name-style="western"><surname>Jakab</surname><given-names initials="Z">Zsuzsanna</given-names></name><degrees>MD, PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5410-1187</contrib-id><xref rid="cncr34561-aff-0023" ref-type="aff">
<sup>23</sup>
</xref></contrib><contrib id="cncr34561-cr-0028" contrib-type="author"><name name-style="western"><surname>Gunnes</surname><given-names initials="MW">Maria Winther</given-names></name><degrees>MD, PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2514-0547</contrib-id><xref rid="cncr34561-aff-0014" ref-type="aff">
<sup>14</sup>
</xref><xref rid="cncr34561-aff-0024" ref-type="aff">
<sup>24</sup>
</xref></contrib><contrib id="cncr34561-cr-0029" contrib-type="author"><name name-style="western"><surname>Terenziani</surname><given-names initials="M">Monica</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7080-6718</contrib-id><xref rid="cncr34561-aff-0025" ref-type="aff">
<sup>25</sup>
</xref></contrib><contrib id="cncr34561-cr-0030" contrib-type="author"><name name-style="western"><surname>Zaletel</surname><given-names initials="LZ">Lorna Zadravec</given-names></name><degrees>MD, PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4423-0276</contrib-id><xref rid="cncr34561-aff-0026" ref-type="aff">
<sup>26</sup>
</xref></contrib><contrib id="cncr34561-cr-0031" contrib-type="author"><name name-style="western"><surname>Kuehni</surname><given-names initials="CE">Claudia E.</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8957-2002</contrib-id><xref rid="cncr34561-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="cncr34561-aff-0027" ref-type="aff">
<sup>27</sup>
</xref></contrib><contrib id="cncr34561-cr-0032" contrib-type="author"><name name-style="western"><surname>Haupt</surname><given-names initials="R">Riccardo</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0571-8460</contrib-id><xref rid="cncr34561-aff-0028" ref-type="aff">
<sup>28</sup>
</xref></contrib><contrib id="cncr34561-cr-0033" contrib-type="author"><name name-style="western"><surname>de Vathaire</surname><given-names initials="F">Florent</given-names></name><degrees>PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8374-9281</contrib-id><xref rid="cncr34561-aff-0021" ref-type="aff">
<sup>21</sup>
</xref></contrib><contrib id="cncr34561-cr-0034" contrib-type="author"><name name-style="western"><surname>Kremer</surname><given-names initials="LC">Leontien C.</given-names></name><degrees>MD, PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7422-3248</contrib-id><xref rid="cncr34561-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="cncr34561-aff-0029" ref-type="aff">
<sup>29</sup>
</xref></contrib><contrib id="cncr34561-cr-0035" contrib-type="author"><name name-style="western"><surname>L&#228;hteenm&#228;ki</surname><given-names initials="PM">P&#228;ivi M.</given-names></name><degrees>MD, PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5500-9606</contrib-id><xref rid="cncr34561-aff-0030" ref-type="aff">
<sup>30</sup>
</xref></contrib><contrib id="cncr34561-cr-0036" contrib-type="author"><name name-style="western"><surname>Winther</surname><given-names initials="JF">Jeanette F.</given-names></name><degrees>MD, PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3440-5108</contrib-id><xref rid="cncr34561-aff-0008" ref-type="aff">
<sup>8</sup>
</xref><xref rid="cncr34561-aff-0031" ref-type="aff">
<sup>31</sup>
</xref></contrib><contrib id="cncr34561-cr-0037" contrib-type="author"><name name-style="western"><surname>Hjorth</surname><given-names initials="L">Lars</given-names></name><degrees>MD, PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8302-7174</contrib-id><xref rid="cncr34561-aff-0018" ref-type="aff">
<sup>18</sup>
</xref></contrib><contrib id="cncr34561-cr-0038" contrib-type="author"><name name-style="western"><surname>Hawkins</surname><given-names initials="MM">Michael M.</given-names></name><degrees>DPhil</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6496-4800</contrib-id><xref rid="cncr34561-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cncr34561-cr-0039" contrib-type="author" corresp="yes"><name name-style="western"><surname>Reulen</surname><given-names initials="RC">Raoul C.</given-names></name><degrees>PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7328-0467</contrib-id><xref rid="cncr34561-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>r.c.reulen@bham.ac.uk</email></address></contrib></contrib-group><aff content-type="private-address" id="cncr34561-aff-0001">
<label>
<sup>1</sup>
</label>
<institution>Center for Childhood Cancer Survivor Studies</institution>
<institution>Institute of Applied Health Research</institution>
<institution>University of Birmingham</institution>
<city>Birmingham</city>
<country country="GB">UK</country>
</aff><aff content-type="private-address" id="cncr34561-aff-0002">
<label>
<sup>2</sup>
</label>
<institution>Princess Maxima Center for Pediatric Oncology</institution>
<city>Utrecht</city>
<country country="NL">The Netherlands</country>
</aff><aff content-type="private-address" id="cncr34561-aff-0003">
<label>
<sup>3</sup>
</label>
<institution>Childhood Cancer Research Group</institution>
<institution>Institute of Social and Preventive Medicine</institution>
<institution>University of Bern</institution>
<city>Bern</city>
<country country="CH">Switzerland</country>
</aff><aff id="cncr34561-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Center for Primary Care and Public Health (Unisante)</named-content>
<institution>University of Lausanne</institution>
<city>Lausanne</city>
<country country="CH">Switzerland</country>
</aff><aff content-type="private-address" id="cncr34561-aff-0005">
<label>
<sup>5</sup>
</label>
<institution>St Anna Children's Hospital</institution>
<city>Vienna</city>
<country country="AT">Austria</country>
</aff><aff id="cncr34561-aff-0006">
<label>
<sup>6</sup>
</label>
<named-content content-type="organisation-division">Department of Pediatrics and Adolescent Medicine</named-content>
<institution>Johannes Kepler University Linz</institution>
<institution>Kepler University Hospital</institution>
<city>Linz</city>
<country country="AT">Austria</country>
</aff><aff id="cncr34561-aff-0007">
<label>
<sup>7</sup>
</label>
<named-content content-type="organisation-division">Scientific Directorate</named-content>
<institution>IRCCS Istituto Giannina Gaslini</institution>
<city>Genova</city>
<country country="IT">Italy</country>
</aff><aff id="cncr34561-aff-0008">
<label>
<sup>8</sup>
</label>
<named-content content-type="organisation-division">Danish Cancer Society Research Center</named-content>
<institution>Childhood Cancer Research Group</institution>
<city>Copenhagen</city>
<country country="DK">Denmark</country>
</aff><aff content-type="private-address" id="cncr34561-aff-0009">
<label>
<sup>9</sup>
</label>
<institution>Children's Hospital</institution>
<institution>Landspitali University Hospital</institution>
<city>Reykjavik</city>
<country country="IS">Iceland</country>
</aff><aff content-type="private-address" id="cncr34561-aff-0010">
<label>
<sup>10</sup>
</label>
<institution>Great North Children's Hospital</institution>
<institution>Newcastle upon Tyne Hospitals National Health Service Foundation Trust</institution>
<city>Newcastle upon Tyne</city>
<country country="GB">UK</country>
</aff><aff content-type="private-address" id="cncr34561-aff-0011">
<label>
<sup>11</sup>
</label>
<institution>Newcastle University Center for Cancer</institution>
<institution>Newcastle University</institution>
<city>Newcastle upon Tyne</city>
<country country="GB">UK</country>
</aff><aff id="cncr34561-aff-0012">
<label>
<sup>12</sup>
</label>
<named-content content-type="organisation-division">Department of Health Sciences and Medicine</named-content>
<institution>University of Lucerne</institution>
<city>Lucerne</city>
<country country="CH">Switzerland</country>
</aff><aff content-type="private-address" id="cncr34561-aff-0013">
<label>
<sup>13</sup>
</label>
<institution>Boyne Research Institute</institution>
<city>Bettystown</city>
<named-content content-type="country-part">Co Meath</named-content>
<country country="IE">Ireland</country>
</aff><aff content-type="private-address" id="cncr34561-aff-0014">
<label>
<sup>14</sup>
</label>
<institution>Division of Pediatric and Adolescent Medicine</institution>
<institution>Oslo University Hospital Rikshospitalet</institution>
<city>Oslo</city>
<country country="NO">Norway</country>
</aff><aff id="cncr34561-aff-0015">
<label>
<sup>15</sup>
</label>
<named-content content-type="organisation-division">Pediatric Clinic</named-content>
<institution>University of Milano&#8208;Bicocca</institution>
<institution>Hospital San Gerardo</institution>
<city>Monza</city>
<country country="IT">Italy</country>
</aff><aff content-type="private-address" id="cncr34561-aff-0016">
<label>
<sup>16</sup>
</label>
<institution>University Children's Hospital Ljubljana</institution>
<institution>University Medical Center Ljubljana</institution>
<city>Ljubljana</city>
<country country="SI">Slovenia</country>
</aff><aff id="cncr34561-aff-0017">
<label>
<sup>17</sup>
</label>
<named-content content-type="organisation-division">Department of Hematology</named-content>
<institution>Radboud University Medical Center</institution>
<city>Nijmegen</city>
<country country="NL">Netherlands</country>
</aff><aff id="cncr34561-aff-0018">
<label>
<sup>18</sup>
</label>
<named-content content-type="organisation-division">Department of Clinical Sciences Lund, Pediatrics</named-content>
<institution>Lund University</institution>
<institution>Skane University Hospital</institution>
<city>Lund</city>
<country country="SE">Sweden</country>
</aff><aff id="cncr34561-aff-0019">
<label>
<sup>19</sup>
</label>
<named-content content-type="organisation-division">Childhood Cancer Registry of Piedmont</named-content>
<named-content content-type="organisation-division">Cancer Epidemiology Unit</named-content>
<named-content content-type="organisation-division">Department of Medical Sciences</named-content>
<institution>University of Turin</institution>
<city>Turin</city>
<country country="IT">Italy</country>
</aff><aff content-type="private-address" id="cncr34561-aff-0020">
<label>
<sup>20</sup>
</label>
<institution>Reference Center for Epidemiology and Cancer Prevention&#8208;Piemonte</institution>
<institution>University Hospital Citta della Salute e della Scienza di Torino</institution>
<city>Turin</city>
<country country="IT">Italy</country>
</aff><aff id="cncr34561-aff-0021">
<label>
<sup>21</sup>
</label>
<named-content content-type="organisation-division">Radiation Epidemiology Team</named-content>
<named-content content-type="organisation-division">Center for Research in Epidemiology and Population Health</named-content>
<institution>National Institute of Health and Medical Research Unit 1018</institution>
<institution>University Paris Saclay</institution>
<institution>Gustave Roussy</institution>
<city>Villejuif</city>
<country country="FR">France</country>
</aff><aff id="cncr34561-aff-0022">
<label>
<sup>22</sup>
</label>
<named-content content-type="organisation-division">German Childhood Cancer Registry</named-content>
<institution>Division of Childhood Cancer Epidemiology</institution>
<institution>Institute of Medical Biostatistics, Epidemiology, and Informatics</institution>
<institution>Johannes&#8208;Gutenberg University Mainz</institution>
<city>Mainz</city>
<country country="DE">Germany</country>
</aff><aff id="cncr34561-aff-0023">
<label>
<sup>23</sup>
</label>
<named-content content-type="organisation-division">Hungarian Childhood Cancer Registry</named-content>
<named-content content-type="organisation-division">Second Department of Pediatrics</named-content>
<institution>Semmelweis University</institution>
<city>Budapest</city>
<country country="HU">Hungary</country>
</aff><aff id="cncr34561-aff-0024">
<label>
<sup>24</sup>
</label>
<named-content content-type="organisation-division">Department of Registration</named-content>
<institution>Cancer Registry of Norway</institution>
<city>Oslo</city>
<country country="NO">Norway</country>
</aff><aff content-type="private-address" id="cncr34561-aff-0025">
<label>
<sup>25</sup>
</label>
<institution>Pediatric Oncology Unit</institution>
<institution>Fondazione IRCCS Istituto Nazionale dei Tumori</institution>
<city>Milan</city>
<country country="IT">Italy</country>
</aff><aff content-type="private-address" id="cncr34561-aff-0026">
<label>
<sup>26</sup>
</label>
<institution>Division of Radiotherapy</institution>
<institution>Institute of Oncology</institution>
<city>Ljubljana</city>
<country country="SI">Slovenia</country>
</aff><aff id="cncr34561-aff-0027">
<label>
<sup>27</sup>
</label>
<named-content content-type="organisation-division">Division of Pediatric Hematology/Oncology</named-content>
<named-content content-type="organisation-division">Department of Pediatrics</named-content>
<institution>University Children's Hospital of Bern</institution>
<institution>University of Bern</institution>
<city>Bern</city>
<country country="CH">Switzerland</country>
</aff><aff id="cncr34561-aff-0028">
<label>
<sup>28</sup>
</label>
<named-content content-type="organisation-division">Diagnosis, Observation, Prevention After Oncologic Treatment (DOPO) Clinic</named-content>
<institution>Division of Hematology/Oncology</institution>
<institution>IRCCS Istituto Giannina Gaslini</institution>
<city>Genova</city>
<country country="IT">Italy</country>
</aff><aff content-type="private-address" id="cncr34561-aff-0029">
<label>
<sup>29</sup>
</label>
<institution>Emma Children's Hospital</institution>
<city>Amsterdam</city>
<country country="NL">Netherlands</country>
</aff><aff id="cncr34561-aff-0030">
<label>
<sup>30</sup>
</label>
<named-content content-type="organisation-division">Department of Pediatrics and Adolescent Medicine</named-content>
<institution>Turku University and Turku University Hospital</institution>
<city>Turku</city>
<country country="FI">Finland</country>
</aff><aff id="cncr34561-aff-0031">
<label>
<sup>31</sup>
</label>
<named-content content-type="organisation-division">Department of Clinical Medicine</named-content>
<institution>Faculty of Health</institution>
<institution>Aarhus University and University Hospital</institution>
<city>Aarhus</city>
<country country="DK">Denmark</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Raoul C. Reulen, Centre for Childhood Cancer Survivor Studies, Institute of Applied Health Research, Robert Aitken Building, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.<break/>
Email: <email>r.c.reulen@bham.ac.uk</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>29</day><month>11</month><year>2022</year></pub-date><pub-date pub-type="ppub"><day>01</day><month>2</month><year>2023</year></pub-date><volume>129</volume><issue seq="140">3</issue><issue-id pub-id-type="pmc-issue-id">433423</issue-id><issue-id pub-id-type="doi">10.1002/cncr.v129.3</issue-id><fpage>426</fpage><lpage>440</lpage><history><date date-type="rev-recd"><day>02</day><month>10</month><year>2022</year></date><date date-type="received"><day>05</day><month>7</month><year>2022</year></date><date date-type="accepted"><day>03</day><month>10</month><year>2022</year></date></history><pub-history><event event-type="pmc-release"><date><day>13</day><month>04</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>14</day><month>04</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-02-20 00:25:28.243"><day>20</day><month>02</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2022 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="CNCR-129-426.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:CNCR-129-426.pdf"/><abstract><title>Abstract</title><sec id="cncr34561-sec-0001"><title>Background</title><p>Survivors of Hodgkin lymphoma (HL) are at risk of developing non&#8208;Hodgkin lymphoma (NHL) after treatment; however, the risks of developing subsequent primary lymphomas (SPLs), including HL and NHL, after different types of childhood cancer are unknown. The authors quantified the risk of SPLs using the largest cohort of childhood cancer survivors worldwide.</p></sec><sec id="cncr34561-sec-0002"><title>Methods</title><p>The Pan&#8208;European Network for Care of Survivors After Childhood and Adolescent Cancer (PanCare) Survivor Care and Follow&#8208;Up Studies (PanCareSurFup) cohort includes 69,460 five&#8208;year survivors of childhood cancer, diagnosed during 1940 through 2008, from 12 European countries. Risks of SPLs were quantified by standardized incidence ratios (SIRs) and relative risks (RRs) using multivariable Poisson regression.</p></sec><sec id="cncr34561-sec-0003"><title>Results</title><p>Overall, 140 SPLs, including 104 NHLs and 36 HLs, were identified. Survivors were at 60% increased risk of an SPL compared with the general population (SIR, 1.6; 95% confidence interval [CI], 1.4&#8211;1.9). Survivors were twice as likely to develop NHL (SIR, 2.3; 95% CI, 1.9&#8211;2.8), with the greatest risks among survivors of HL (SIR, 7.1; 95% CI, 5.1&#8211;10.0), Wilms tumor (SIR, 3.1; 95% CI, 1.7&#8211;5.7), leukemia (SIR, 2.8; 95% CI, 1.8&#8211;4.4), and bone sarcoma (SIR, 2.7; 95% CI, 1.4&#8211;5.4). Treatment with chemotherapy for any cancer doubled the RR of NHL (RR, 2.1; 95% CI, 1.2&#8211;3.9), but treatment with radiotherapy did not (RR, 1.2; 95% CI, 0.7&#8211;2.0). Survivors were at similar risk of developing a subsequent HL as the general population (SIR, 1.1; 95% CI, 0.8&#8211;1.5).</p></sec><sec id="cncr34561-sec-0004"><title>Conclusions</title><p>In addition to HL, the authors show here for the first time that survivors of Wilms tumor, leukemia, and bone sarcoma are at risk of NHL. Survivors and health care professionals should be aware of the risk of NHL in these survivors and in any survivors treated with chemotherapy.</p></sec></abstract><abstract abstract-type="short"><p>Using data from 69,460 five&#8208;year survivors of childhood cancer across Europe, the authors investigated the risks of subsequent primary lymphoma within the largest cohort reported to date. Novel findings include the identification of an increased risk of non&#8208;Hodgkin lymphoma among survivors of Wilms tumor, leukemia, and bone sarcoma and in any survivors treated with chemotherapy.</p></abstract><kwd-group><kwd id="cncr34561-kwd-0001">childhood cancer survivors</kwd><kwd id="cncr34561-kwd-0002">Hodgkin lymphoma</kwd><kwd id="cncr34561-kwd-0003">late effects</kwd><kwd id="cncr34561-kwd-0004">non&#8208;Hodgkin lymphoma</kwd><kwd id="cncr34561-kwd-0005">second cancers</kwd><kwd id="cncr34561-kwd-0006">subsequent primary lymphoma</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>European Union's Seventh Framework Programme for research, technological development and demonstration</funding-source><award-id>257505</award-id></award-group><award-group id="funding-0002"><funding-source>The Foundation Force de recherche sur le cancer de l'enfant (FORCE), The Italian Association for Cancer Research and the Compagnia</funding-source></award-group><award-group id="funding-0003"><funding-source>San Paolo</funding-source></award-group><award-group id="funding-0004"><funding-source>The Fondo Chiara Rama ONLUS</funding-source></award-group><award-group id="funding-0005"><funding-source>The Swedish Childhood Cancer Fund</funding-source></award-group><award-group id="funding-0006"><funding-source>The French Association for Cancer Research (ARC)</funding-source></award-group><award-group id="funding-0007"><funding-source>The French National Agency for Research (ANR) (Hope&#8208;Epi project)</funding-source></award-group><award-group id="funding-0008"><funding-source>The French National Cancer Institute (INCA)</funding-source></award-group><award-group id="funding-0009"><funding-source>Pfizer Foundation for Children and Adolescent Health</funding-source></award-group><award-group id="funding-0010"><funding-source>Slovenian Research Agency</funding-source></award-group><award-group id="funding-0011"><funding-source>The Swiss Paediatric Oncology Group</funding-source></award-group><award-group id="funding-0012"><funding-source>The Swiss Cancer League</funding-source><award-id>KLS&#8208;3412&#8208;02&#8208;2014</award-id><award-id>KLS&#8208;3886&#8208;02&#8208;2016</award-id><award-id>KLS&#8208;5432&#8208;08&#8208;2021</award-id></award-group><award-group id="funding-0013"><funding-source>The Swiss Cancer Research foundation</funding-source><award-id>KFS&#8208;02783&#8208;02&#8208;2011</award-id><award-id>KFS&#8208;4157&#8208;02&#8208;2017</award-id><award-id>KLA/KFS&#8208;4825&#8208;01&#8208;2019</award-id><award-id>KFS&#8208;4722&#8208;02&#8208;2019</award-id><award-id>KFS&#8208;5302&#8208;02&#8208;2021</award-id></award-group><award-group id="funding-0014"><funding-source>The Swiss National Science Foundation</funding-source><award-id>PDFMP3_141775</award-id></award-group><award-group id="funding-0015"><funding-source>The Dutch Cancer Society</funding-source><award-id>DCOG2011&#8208;5027</award-id><award-id>UVA2012&#8208;5517</award-id></award-group><award-group id="funding-0016"><funding-source>The Norwegian Childhood Cancer Foundation, and Children with Cancer UK</funding-source><award-id>20457</award-id></award-group></funding-group><counts><fig-count count="1"/><table-count count="4"/><page-count count="15"/><word-count count="8536"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>1 February 2023</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.2.7 mode:remove_FC converted:13.04.2023</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="cncr34561-cit-0041"><string-name name-style="western"><surname>Dudley</surname><given-names>IM</given-names></string-name>, <string-name name-style="western"><surname>Sunguc</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Heymer</surname><given-names>EJ</given-names></string-name>, et al. <article-title>Risk of subsequent primary lymphoma in a cohort of 69,460 five&#8208;year survivors of childhood and adolescent cancer in Europe: the PanCareSurFup study</article-title>. <source>Cancer</source>. <year>2023</year>;<volume>129</volume>(<issue>3</issue>):<fpage>426</fpage>&#8208;<lpage>440</lpage>. doi:<pub-id pub-id-type="doi">10.1002/cncr.34561</pub-id><pub-id pub-id-type="pmid">36444554</pub-id><pub-id pub-id-type="pmcid">PMC10099796</pub-id></mixed-citation>
</p><fn-group><fn id="cncr34561-note-0001"><p>Coauthor Stanislaw Garwicz MD died November 27, 2018. This work is dedicated to him.</p></fn></fn-group></notes></front><body id="cncr34561-body-0001"><sec id="cncr34561-sec-0010"><title>INTRODUCTION</title><p>Approximately 35,000 children and adolescents are diagnosed with cancer in Europe each year.<xref rid="cncr34561-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> Since the 1970s, 5&#8208;year survival rates have improved dramatically and now reach 80% in most European countries, mostly because of combined chemotherapy modalities and improvements in the delivery of radiotherapy.<xref rid="cncr34561-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="cncr34561-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="cncr34561-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> There are currently over 500,000 childhood cancer survivors in Europe, and this number continues to increase.<xref rid="cncr34561-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> The risk of premature morbidity and mortality for childhood cancer survivors compared with the general population is well documented, with many health risks arising 20&#8211;30&#160;years after a childhood cancer diagnosis. Approximately 60% of childhood cancer survivors develop at least one chronic health condition during their lifetime, and more than one in four develop severe or life&#8208;threatening diseases.<xref rid="cncr34561-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="cncr34561-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>
</p><p>A serious long&#8208;term consequence of treatment of childhood cancer is the increased risk of developing subsequent primary neoplasms, which is in the range of three to five times greater that of the general population.<xref rid="cncr34561-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="cncr34561-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="cncr34561-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="cncr34561-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> Existing evidence suggests that survivors are at increased risk of several types of subsequent primary neoplasms, particularly central nervous system tumors; nonmelanoma skin cancer; and digestive, breast, bone, and genitourinary cancers. Limited numbers of studies have shown that the overall risk of subsequent primary lymphoma (SPL) is also increased<xref rid="cncr34561-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="cncr34561-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="cncr34561-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="cncr34561-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>; however, to our knowledge, few previous large&#8208;scale studies have comprehensively investigated the risk of developing SPLs among childhood cancer survivors&#8212;with the largest previous study to date including 45 SPLs.<xref rid="cncr34561-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> Studies of survivors of Hodgkin lymphoma (HL) have found an increased risk of non&#8208;Hodgkin lymphoma (NHL) but mostly included HL survivors who were diagnosed in adulthood.<xref rid="cncr34561-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>, <xref rid="cncr34561-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="cncr34561-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="cncr34561-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="cncr34561-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>, <xref rid="cncr34561-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>, <xref rid="cncr34561-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="cncr34561-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>, <xref rid="cncr34561-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>, <xref rid="cncr34561-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> To date, no large&#8208;scale study has characterized the risks of SPLs and of specific SPLs by type of childhood cancer, sex, age at diagnosis, decade of diagnosis, attained age, and treatment factors. Identification of those survivors at highest risk of an SPL would be important for informing survivors and health care professionals of who is at risk, potentially detecting SPLs early, and may give clues about potential biologic mechanisms.</p><p>The principal aim of this largest ever cohort study was to quantify the risk of developing an SPL, further subdivided into HL and NHL, among 69,460 survivors of childhood cancer within Europe and compare this risk with that in the general population, including three times the number of SPLs compared with the largest previous study to date.<xref rid="cncr34561-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> Secondary aims included investigating variations in risk, which may be associated with certain demographic and oncologic factors, and assessing the level of risk sustained in the long term (beyond age 40&#160;years).</p></sec><sec id="cncr34561-sec-0020"><title>MATERIALS AND METHODS</title><sec id="cncr34561-sec-0030"><title>PanCare Childhood and Adolescent Cancer Survivor Care and Follow&#8208;Up Studies</title><p>The Pan&#8208;European Network for Care of Survivors after Childhood and Adolescent Cancer (PanCare) is a network of health care professionals, researchers, childhood cancer survivors, and their families that aims to improve both the care and the quality of life for survivors of childhood cancer.<xref rid="cncr34561-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> Funded by the seventh Framework Program of the European Union, a consortium among several institutions of PanCare members established the largest ever collaborative, comprehensive study for childhood cancer survivors: <italic toggle="yes">The PanCare Childhood and Adolescent Cancer Survivor Care and Follow&#8208;Up Studies</italic> (PanCareSurFup). The overall objectives of PanCareSurFup are to investigate long&#8208;term health risks for childhood cancer survivors, establish clinical guidelines for their follow&#8208;up care, and disseminate research results.<xref rid="cncr34561-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="cncr34561-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>, <xref rid="cncr34561-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> The PanCareSurFup cohort comprises data from 5&#8208;year survivors of childhood cancer (diagnosed at ages birth to 20&#160;years between 1940 and 2008) across 12 European countries: France, Italy, Hungary, the Netherlands, Denmark, Sweden, Norway, Finland, Iceland, Slovenia, Switzerland, and the United Kingdom (see Table S1). Data were sourced from both population&#8208;based cancer registries and major treatment centers. Ethical approval and consent for data collection were obtained from the ethical and legal bodies in each of the respective countries contributing to PanCareSurFup. Ethical approval was not obtained specifically for this study because it involved pooling of nonidentifiable data.</p></sec><sec id="cncr34561-sec-0040"><title>Childhood cancer classification</title><p>Because of various practices across different countries in terms of childhood cancer registration, the cancer site and the type of childhood cancer were coded using a range of classification systems. To standardize this across the pooled cohort, all childhood tumor classification codes were converted into codes from the third revision of the <italic toggle="yes">International Classification of Diseases for Oncology</italic> using the Cancer Registry Tools Program.<xref rid="cncr34561-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref>, <xref rid="cncr34561-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> These were then categorised into childhood cancers subgroups according to&#160;the <italic toggle="yes">International Classification of Childhood Cancer</italic>, third edition.<xref rid="cncr34561-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref> Individuals were excluded from the pooled cohort if: (1) they had a primary diagnosis of myelodysplastic syndrome, Langerhans cell histiocytosis, or chronic myeloproliferative or lymphoproliferative disorders; (2) tumor coding was nonmalignant, except for intracranial and bladder tumors; and (3) tumor codes were not classifiable according to the third revision of the <italic toggle="yes">International Classification of Childhood Cancer</italic>.</p></sec><sec id="cncr34561-sec-0050"><title>Identification of subsequent primary lymphomas</title><p>SPLs were ascertained using various methods, primarily through population&#8208;based cancer registries and follow&#8208;up clinics and validated through pathology reports or other means of clinical diagnosis. The SPLs were classified by site according to the <italic toggle="yes">International Classification of Diseases</italic> using the revision appropriate to the year of diagnosis (see Table S2). For inclusion as an SPL, the subsequent lymphoma had to have a different morphology classification than the original childhood cancer, as defined by the <italic toggle="yes">International Classification of Diseases for Oncology</italic>, third edition classification. In addition, we excluded subsequent NHLs diagnosed after a primary NHL in childhood (<italic toggle="yes">N</italic>&#160;=&#160;8) and subsequent HLs after a primary HL (<italic toggle="yes">N</italic>&#160;=&#160;1), regardless of any difference in morphology. Also, all NHL survivors were excluded from analyses relating to subsequent NHLs, and all HL survivors were excluded from analyses relating to subsequent HLs.</p></sec><sec id="cncr34561-sec-0060"><title>Statistical analysis</title><p>Individuals entered the cohort at 5&#8208;year survival from childhood cancer diagnosis and remained at risk of an SPL until the first occurrence of loss to follow&#8208;up, death, or study exit date. Standardized incidence ratios (SIRs) were calculated as the ratio of the observed to expected numbers of lymphomas. Expected rates were calculated by accruing person&#8208;years at risk stratified by age, country, sex, and calendar year, and multiplying by the equivalent lymphoma incidence rates for the general population.<xref rid="cncr34561-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref> General population incidence rates (also stratified by age, country, sex, and calendar year) were obtained from the <italic toggle="yes">Cancer Incidence in Five Continents</italic> project.<xref rid="cncr34561-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref> Site&#8208;specific incidence rates do not exist for Hungary, hence these were estimated using Slovakian incidence rates because it is their neighboring country with similar demographic characteristics.<xref rid="cncr34561-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref> Absolute excess risks (AERs) were calculated as the observed minus the expected number of lymphomas, divided by person&#8208;years at risk, and multiplied by 100,000. This can be interpreted as the number of excess lymphomas observed beyond those expected per 100,000 person&#8208;years. Multivariable Poisson regression models were fitted to estimate the relative risk (RR) of all SPLs and subsequent primary NHLs and HLs while adjusting for the effect of potentially confounding factors: sex, childhood cancer diagnosis, country, decade of childhood diagnosis, age at childhood diagnosis, and attained age. RRs can be interpreted as the ratio of SIRs, adjusted for potential confounders. Likelihood&#8208;ratio tests were applied to generate <italic toggle="yes">p</italic> values for linear trend for ordinal factors of interest or heterogeneity for nominal variables. Because of a relatively small number of observations in subsequent primary HLs, AERs could not be calculated.</p><p>SIRs, AERs, and RRs were calculated for the treatment factors radiotherapy (<italic toggle="yes">yes/no</italic>) and chemotherapy (<italic toggle="yes">yes/no</italic>) for those countries where &lt;30% of treatment data were missing. Therefore, the Nordic countries and an Italian population&#8208;based cohort were completely excluded from analyses involving treatment variables regardless of whether treatment data were available to avoid potential bias. By using this approach, for 10.5% of survivors, the radiotherapy data were missing; and, for 12.4% of survivors, the chemotherapy data were missing. In all, information on radiotherapy was available for 90 SPLs, and information on chemotherapy was available for 88 SPLs.</p><p>To assess the probability of developing an SPL with increasing attained age, the cumulative incidence accounting for the competing risk of death was estimated for types of childhood cancer with &#8805;20 observed SPLs. All statistical analyses were conducted in Stata software (Stata Corporation).<xref rid="cncr34561-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref> All analyses were based on complete case analysis (i.e., list&#8208;wise deletion). A two&#8208;sided <italic toggle="yes">p</italic> value &lt; .05 was considered statistically significant.</p></sec></sec><sec id="cncr34561-sec-0070"><title>RESULTS</title><sec id="cncr34561-sec-0080"><title>Cohort characteristics</title><p>Among 69,460 five&#8208;year survivors of childhood cancer, in total, 1,264,624 person&#8208;years were accrued, with loss to follow&#8208;up not exceeding 6% in any country (see Table S1). Over the follow&#8208;up period, 140 SPLs were observed in survivors across an age range from 5 to 88&#160;years. From the 140 SPLs, 104 (74.2%) were classified as NHL, and 36 (25.7%) were classified as HL. Most of the SPLs occurred in males (66.4%) and in those surviving HL (<italic toggle="yes">n</italic>&#160;=&#160;33) and leukemia (<italic toggle="yes">n</italic>&#160;=&#160;31; Table&#160;<xref rid="cncr34561-tbl-0001" ref-type="table">1</xref>).</p><table-wrap position="float" id="cncr34561-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Characteristics of 69,460 five&#8208;year survivors in the PanCareSurFup cohort and of the 140 individuals who developed a subsequent primary lymphoma (further subdivided into non&#8208;Hodgkin and Hodgkin lymphoma, respectively)</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="left" valign="bottom" rowspan="1" colspan="1"/><th colspan="4" align="left" valign="bottom" rowspan="1">No. of survivors (%)</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Factor</th><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="left" valign="bottom" rowspan="1" colspan="1">PanCareSurFup cohort</th><th align="left" valign="bottom" rowspan="1" colspan="1">All lymphoma</th><th align="left" valign="bottom" rowspan="1" colspan="1">Non&#8208;Hodgkin lymphoma</th><th align="left" valign="bottom" rowspan="1" colspan="1">Hodgkin lymphoma</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Overall</td><td align="left" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="left" valign="top" rowspan="1" colspan="1">69,460 (100.0)</td><td align="left" valign="top" rowspan="1" colspan="1">140 (100.0)</td><td align="left" valign="top" rowspan="1" colspan="1">104 (100.0)</td><td align="left" valign="top" rowspan="1" colspan="1">36 (100.0)</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">Sex</td><td align="left" valign="top" rowspan="1" colspan="1">Male</td><td align="left" valign="top" rowspan="1" colspan="1">37,738 (54.3)</td><td align="left" valign="top" rowspan="1" colspan="1">93 (66.4)</td><td align="left" valign="top" rowspan="1" colspan="1">67 (64.4)</td><td align="left" valign="top" rowspan="1" colspan="1">26 (72.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Female</td><td align="left" valign="top" rowspan="1" colspan="1">31,722 (45.7)</td><td align="left" valign="top" rowspan="1" colspan="1">47 (33.6)</td><td align="left" valign="top" rowspan="1" colspan="1">37 (35.6)</td><td align="left" valign="top" rowspan="1" colspan="1">10 (28.0)</td></tr><tr><td rowspan="13" align="left" valign="top" colspan="1">Childhood cancer diagnosis</td><td align="left" valign="top" rowspan="1" colspan="1">Leukemia</td><td align="left" valign="top" rowspan="1" colspan="1">16,646 (24.0)</td><td align="left" valign="top" rowspan="1" colspan="1">31 (22.1)</td><td align="left" valign="top" rowspan="1" colspan="1">19 (18.3)</td><td align="left" valign="top" rowspan="1" colspan="1">12 (33.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hodgkin lymphoma</td><td align="left" valign="top" rowspan="1" colspan="1">6046 (8.7)</td><td align="left" valign="top" rowspan="1" colspan="1">33 (23.6)</td><td align="left" valign="top" rowspan="1" colspan="1">33 (31.7)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Non&#8208;Hodgkin lymphoma</td><td align="left" valign="top" rowspan="1" colspan="1">4078 (5.9)</td><td align="left" valign="top" rowspan="1" colspan="1">5 (3.6)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">5 (14.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CNS tumors</td><td align="left" valign="top" rowspan="1" colspan="1">14,592 (21.0)</td><td align="left" valign="top" rowspan="1" colspan="1">14 (10.0)</td><td align="left" valign="top" rowspan="1" colspan="1">9 (8.7)</td><td align="left" valign="top" rowspan="1" colspan="1">5 (14.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Neuroblastoma</td><td align="left" valign="top" rowspan="1" colspan="1">3178 (4.6)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (2.9)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (2.9)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (3.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Retinoblastoma</td><td align="left" valign="top" rowspan="1" colspan="1">2590 (3.7)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (2.1)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (1.9)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (3.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Wilms tumor</td><td align="left" valign="top" rowspan="1" colspan="1">4783 (6.9)</td><td align="left" valign="top" rowspan="1" colspan="1">14 (10.0)</td><td align="left" valign="top" rowspan="1" colspan="1">10 (9.6)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (11.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Bone sarcoma</td><td align="left" valign="top" rowspan="1" colspan="1">3173 (4.6)</td><td align="left" valign="top" rowspan="1" colspan="1">10 (7.1)</td><td align="left" valign="top" rowspan="1" colspan="1">8 (7.7)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (6.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Soft tissue sarcoma</td><td align="left" valign="top" rowspan="1" colspan="1">4531 (6.5)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (2.9)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (1.9)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (6.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Thyroid carcinoma</td><td align="left" valign="top" rowspan="1" colspan="1">1295 (1.9)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (2.9)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (2.9)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (3.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Gonadal</td><td align="left" valign="top" rowspan="1" colspan="1">2721 (3.9)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (1.4)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (1.9)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Malignant melanoma</td><td align="left" valign="top" rowspan="1" colspan="1">1458 (2.1)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (2.9)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (2.9)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (3.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Other<xref rid="cncr34561-note-0003" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">4369 (6.3)</td><td align="left" valign="top" rowspan="1" colspan="1">12 (8.6)</td><td align="left" valign="top" rowspan="1" colspan="1">10 (9.6)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (6.0)</td></tr><tr><td rowspan="13" align="left" valign="top" colspan="1">Data provider country</td><td align="left" valign="top" rowspan="1" colspan="1">France</td><td align="left" valign="top" rowspan="1" colspan="1">3138 (4.5)</td><td align="left" valign="top" rowspan="1" colspan="1">8 (5.7)</td><td align="left" valign="top" rowspan="1" colspan="1">7 (6.7)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (3.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hungary</td><td align="left" valign="top" rowspan="1" colspan="1">4885 (7.0)</td><td align="left" valign="top" rowspan="1" colspan="1">8 (5.7)</td><td align="left" valign="top" rowspan="1" colspan="1">7 (6.7)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (3.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Italy, population&#8208;based<xref rid="cncr34561-note-0004" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">7476 (10.8)</td><td align="left" valign="top" rowspan="1" colspan="1">6 (4.3)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (2.9)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (8.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Italy, hospital&#8208;based<xref rid="cncr34561-note-0005" ref-type="table-fn">
<sup>c</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">1490 (2.1)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (2.1)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (2.9)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Netherlands</td><td align="left" valign="top" rowspan="1" colspan="1">6044 (8.7)</td><td align="left" valign="top" rowspan="1" colspan="1">15 (10.7)</td><td align="left" valign="top" rowspan="1" colspan="1">9 (8.7)</td><td align="left" valign="top" rowspan="1" colspan="1">6 (17.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Denmark</td><td align="left" valign="top" rowspan="1" colspan="1">4840 (7.0)</td><td align="left" valign="top" rowspan="1" colspan="1">5 (3.6)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (1.9)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (8.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sweden</td><td align="left" valign="top" rowspan="1" colspan="1">7709 (11.1)</td><td align="left" valign="top" rowspan="1" colspan="1">15 (10.7)</td><td align="left" valign="top" rowspan="1" colspan="1">9 (8.7)</td><td align="left" valign="top" rowspan="1" colspan="1">6 (17.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Norway</td><td align="left" valign="top" rowspan="1" colspan="1">3783 (5.4)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Finland</td><td align="left" valign="top" rowspan="1" colspan="1">6229 (9.0)</td><td align="left" valign="top" rowspan="1" colspan="1">19 (13.6)</td><td align="left" valign="top" rowspan="1" colspan="1">16 (15.4)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (8.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Iceland</td><td align="left" valign="top" rowspan="1" colspan="1">275 (0.4)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Slovenia</td><td align="left" valign="top" rowspan="1" colspan="1">1252 (1.8)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (0.7)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (1.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Switzerland</td><td align="left" valign="top" rowspan="1" colspan="1">4379 (6.3)</td><td align="left" valign="top" rowspan="1" colspan="1">7 (5.0)</td><td align="left" valign="top" rowspan="1" colspan="1">5 (4.8)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (6.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">United Kingdom</td><td align="left" valign="top" rowspan="1" colspan="1">17,960 (25.9)</td><td align="left" valign="top" rowspan="1" colspan="1">53 (37.9)</td><td align="left" valign="top" rowspan="1" colspan="1">42 (40.4)</td><td align="left" valign="top" rowspan="1" colspan="1">11 (31.0)</td></tr><tr><td rowspan="4" align="left" valign="top" colspan="1">Decade of childhood cancer diagnosis</td><td align="left" valign="top" rowspan="1" colspan="1">&lt;1970</td><td align="left" valign="top" rowspan="1" colspan="1">8993 (12.9)</td><td align="left" valign="top" rowspan="1" colspan="1">39 (27.9)</td><td align="left" valign="top" rowspan="1" colspan="1">28 (26.9)</td><td align="left" valign="top" rowspan="1" colspan="1">11 (31.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">1970&#8211;1979</td><td align="left" valign="top" rowspan="1" colspan="1">13,479 (19.4)</td><td align="left" valign="top" rowspan="1" colspan="1">39 (27.9)</td><td align="left" valign="top" rowspan="1" colspan="1">30 (28.8)</td><td align="left" valign="top" rowspan="1" colspan="1">9 (25.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">1980&#8211;1989</td><td align="left" valign="top" rowspan="1" colspan="1">20,900 (30.1)</td><td align="left" valign="top" rowspan="1" colspan="1">44 (31.4)</td><td align="left" valign="top" rowspan="1" colspan="1">33 (31.7)</td><td align="left" valign="top" rowspan="1" colspan="1">11 (31.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">1990&#8211;2008</td><td align="left" valign="top" rowspan="1" colspan="1">26,088 (37.6)</td><td align="left" valign="top" rowspan="1" colspan="1">18 (12.9)</td><td align="left" valign="top" rowspan="1" colspan="1">13 (12.5)</td><td align="left" valign="top" rowspan="1" colspan="1">5 (14.0)</td></tr><tr><td rowspan="4" align="left" valign="top" colspan="1">Age at childhood cancer diagnosis, years</td><td align="left" valign="top" rowspan="1" colspan="1">Birth to 4</td><td align="left" valign="top" rowspan="1" colspan="1">26,696 (38.4)</td><td align="left" valign="top" rowspan="1" colspan="1">40 (28.6)</td><td align="left" valign="top" rowspan="1" colspan="1">27 (26.0)</td><td align="left" valign="top" rowspan="1" colspan="1">13 (36.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">5&#8211;9</td><td align="left" valign="top" rowspan="1" colspan="1">15,743 (22.7)</td><td align="left" valign="top" rowspan="1" colspan="1">31 (22.1)</td><td align="left" valign="top" rowspan="1" colspan="1">21 (20.2)</td><td align="left" valign="top" rowspan="1" colspan="1">10 (28.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">10&#8211;14</td><td align="left" valign="top" rowspan="1" colspan="1">15,491 (22.3)</td><td align="left" valign="top" rowspan="1" colspan="1">45 (32.1)</td><td align="left" valign="top" rowspan="1" colspan="1">37 (35.6)</td><td align="left" valign="top" rowspan="1" colspan="1">8 (22.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">15&#8211;20</td><td align="left" valign="top" rowspan="1" colspan="1">11,530 (16.6)</td><td align="left" valign="top" rowspan="1" colspan="1">24 (17.1)</td><td align="left" valign="top" rowspan="1" colspan="1">19 (18.3)</td><td align="left" valign="top" rowspan="1" colspan="1">5 (14.0)</td></tr><tr><td rowspan="5" align="left" valign="top" colspan="1">Attained age, years<xref rid="cncr34561-note-0006" ref-type="table-fn">
<sup>d</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">&lt;20</td><td align="left" valign="top" rowspan="1" colspan="1">15,405 (22.2)</td><td align="left" valign="top" rowspan="1" colspan="1">35 (25.0)</td><td align="left" valign="top" rowspan="1" colspan="1">23 (22.1)</td><td align="left" valign="top" rowspan="1" colspan="1">12 (33.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">20&#8211;29</td><td align="left" valign="top" rowspan="1" colspan="1">18,877 (27.2)</td><td align="left" valign="top" rowspan="1" colspan="1">39 (27.9)</td><td align="left" valign="top" rowspan="1" colspan="1">27 (26.0)</td><td align="left" valign="top" rowspan="1" colspan="1">12 (33.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">30&#8211;39</td><td align="left" valign="top" rowspan="1" colspan="1">17,144 (24.7)</td><td align="left" valign="top" rowspan="1" colspan="1">24 (17.1)</td><td align="left" valign="top" rowspan="1" colspan="1">16 (15.4)</td><td align="left" valign="top" rowspan="1" colspan="1">8 (22.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">40&#8211;49</td><td align="left" valign="top" rowspan="1" colspan="1">10,970 (15.8)</td><td align="left" valign="top" rowspan="1" colspan="1">24 (17.1)</td><td align="left" valign="top" rowspan="1" colspan="1">20 (19.2)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (11.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8805;50</td><td align="left" valign="top" rowspan="1" colspan="1">7064 (10.2)</td><td align="left" valign="top" rowspan="1" colspan="1">18 (12.9)</td><td align="left" valign="top" rowspan="1" colspan="1">18 (17.3)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td rowspan="4" align="left" valign="top" colspan="1">Follow&#8208;up time since 5&#8208;year survival, years<xref rid="cncr34561-note-0006" ref-type="table-fn">
<sup>d</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">0&#8211;9</td><td align="left" valign="top" rowspan="1" colspan="1">23,923 (34.4)</td><td align="left" valign="top" rowspan="1" colspan="1">52 (37.1)</td><td align="left" valign="top" rowspan="1" colspan="1">36 (34.6)</td><td align="left" valign="top" rowspan="1" colspan="1">16 (44.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">10&#8211;19</td><td align="left" valign="top" rowspan="1" colspan="1">15,801 (22.7)</td><td align="left" valign="top" rowspan="1" colspan="1">36 (25.7)</td><td align="left" valign="top" rowspan="1" colspan="1">25 (24.0)</td><td align="left" valign="top" rowspan="1" colspan="1">11 (31.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">20&#8211;29</td><td align="left" valign="top" rowspan="1" colspan="1">16,103 (23.2)</td><td align="left" valign="top" rowspan="1" colspan="1">27 (19.3)</td><td align="left" valign="top" rowspan="1" colspan="1">20 (19.2)</td><td align="left" valign="top" rowspan="1" colspan="1">7 (19.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8805;30</td><td align="left" valign="top" rowspan="1" colspan="1">13,633 (19.6)</td><td align="left" valign="top" rowspan="1" colspan="1">25 (17.9)</td><td align="left" valign="top" rowspan="1" colspan="1">23 (22.1)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (6.0)</td></tr></tbody></table><table-wrap-foot id="cncr34561-ntgp-0001"><fn id="cncr34561-note-0002"><p>Abbreviations: 95% CI, 95% confidence interval; AER, absolute excess risk; CNS, central nervous system; PanCareSurFup, the Pan&#8208;European Network for Care of Survivors After Childhood and Adolescent Cancer (PanCare) Childhood and Adolescent Cancer Survivor Care and Follow&#8208;Up Studies; RR, relative risk; SIR, standardized incidence ratio; SPL, subsequent primary lymphoma.</p></fn><fn id="cncr34561-note-0003"><label>
<sup>a</sup>
</label><p>The category <italic toggle="yes">other</italic> includes: other and unspecified carcinomas (<italic toggle="yes">n</italic>&#160;=&#160;1181), other unspecified malignant tumors (<italic toggle="yes">n</italic>&#160;=&#160;641), malignant extracranial/extragonadal germ cell tumors (<italic toggle="yes">n</italic>&#160;=&#160;433), skin carcinomas (<italic toggle="yes">n</italic>&#160;=&#160;423), unspecified lymphomas (<italic toggle="yes">n</italic>&#160;=&#160;402), hepatoblastoma (<italic toggle="yes">n</italic>&#160;=&#160;319), miscellaneous lymphoreticular neoplasms (<italic toggle="yes">n</italic>&#160;=&#160;279), nasopharyngeal carcinomas (<italic toggle="yes">n</italic>&#160;=&#160;194), renal carcinomas (<italic toggle="yes">n</italic>&#160;=&#160;124), other peripheral nervous cell tumors (<italic toggle="yes">n</italic>&#160;=&#160;94), adrenocortical carcinomas (<italic toggle="yes">n</italic>&#160;=&#160;86), hepatic carcinomas (<italic toggle="yes">n</italic>&#160;=&#160;84), other specified. malignant tumors (<italic toggle="yes">n</italic>&#160;=&#160;59), unspecified malignant renal tumors (<italic toggle="yes">n</italic>&#160;=&#160;35), and unspecified malignant hepatic tumors (<italic toggle="yes">n</italic>&#160;=&#160;15).</p></fn><fn id="cncr34561-note-0004"><label>
<sup>b</sup>
</label><p>Population&#8208;based cohort from the Italian Association of Cancer Registries (AIRTUM).</p></fn><fn id="cncr34561-note-0005"><label>
<sup>c</sup>
</label><p>Hospital&#8208;based registry from the Italian Registry of Off&#8208;Therapy Patients, Genoa.</p></fn><fn id="cncr34561-note-0006"><label>
<sup>d</sup>
</label><p>The number of survivors relates to the highest attained age/follow&#8208;up reached, e.g., at exit of cohort.</p></fn></table-wrap-foot></table-wrap></sec><sec id="cncr34561-sec-0090"><title>Overall risk of any subsequent primary lymphoma</title><p>Overall, childhood cancer survivors were 60% more likely to develop an SPL compared with the expected rates from the general population (SIR, 1.6; 95% CI, 1.4&#8211;1.9), with four additional cases of lymphoma observed per 100,000 person&#8208;years (AER, 4.3; 95% CI, 2.8&#8211;6.6; Table&#160;<xref rid="cncr34561-tbl-0002" ref-type="table">2</xref>). In particular, HL survivors (SIR, 4.1; 95% CI, 2.9&#8211;5.8), but also Wilms tumor (SIR, 2.2; 95% CI, 1.3&#8211;3.8), leukemia (SIR, 2.1; 95% CI, 1.5&#8211;3.0), and bone sarcoma (SIR, 2.1; 95% CI, 1.1&#8211;3.9) survivors, were at increased risk of developing an SPL. Overall, the SIR decreased with increasing attained age (<italic toggle="yes">p</italic> for trend &lt; .001), but the risk was no longer significantly increased beyond age 50 years (SIR, 1.3; 95% CI, 0.8&#8211;2.1). There was a significant increase in SPL risk among those who had received chemotherapy for any childhood cancer compared with those who had not (RR, 1.8; 95% CI, 1.1&#8211;2.9; Table&#160;<xref rid="cncr34561-tbl-0002" ref-type="table">2</xref>), independent of whether or not survivors also had received radiotherapy. The cumulative incidence of developing an SPL by age 65 years was highest after HL, with a probability of developing an SPL of 1.6% (95% CI, 0.7%&#8211;3.1%), whereas only 0.6% was expected based on general population rates (Figure&#160;<xref rid="cncr34561-fig-0001" ref-type="fig">1</xref>).</p><table-wrap position="float" id="cncr34561-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Standardized incidence ratios, relative risks, and absolute excess risks, with 95% confidence intervals, for developing a subsequent primary lymphoma among a cohort of childhood cancer survivors</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Factor</th><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="left" valign="bottom" rowspan="1" colspan="1">Person&#8208;years</th><th align="left" valign="bottom" rowspan="1" colspan="1">Obs/Exp</th><th align="left" valign="bottom" rowspan="1" colspan="1">SIR (95% CI)</th><th align="left" valign="bottom" rowspan="1" colspan="1">RR (95% CI)<xref rid="cncr34561-note-0009" ref-type="table-fn">
<sup>b</sup>
</xref>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">AER (95% CI)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Overall</td><td align="left" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1,264,624</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">140/85.6</td><td align="left" valign="top" rowspan="1" colspan="1">1.6 (1.4&#8211;1.9)</td><td align="left" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="left" valign="top" rowspan="1" colspan="1">4.3 (2.8&#8211;6.6)</td></tr><tr><td rowspan="3" align="left" valign="top" colspan="1">Sex<xref rid="cncr34561-note-0008" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Male</td><td align="char" char="." valign="top" rowspan="1" colspan="1">676,132</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">93/51.5</td><td align="left" valign="top" rowspan="1" colspan="1">1.8 (1.5&#8211;2.2)</td><td align="left" valign="top" rowspan="1" colspan="1">1.0 (Ref)</td><td align="left" valign="top" rowspan="1" colspan="1">6.1 (3.9&#8211;9.7)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Female</td><td align="char" char="." valign="top" rowspan="1" colspan="1">588,492</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">47/34.1</td><td align="left" valign="top" rowspan="1" colspan="1">1.4 (1.0&#8211;1.8)</td><td align="left" valign="top" rowspan="1" colspan="1">0.8 (0.5&#8211;1.1)</td><td align="left" valign="top" rowspan="1" colspan="1">2.2 (0.8&#8211;6.2)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> for heterogeneity</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">.12</td><td align="left" valign="top" rowspan="1" colspan="1">.14</td><td align="left" valign="top" rowspan="1" colspan="1">.03</td></tr><tr><td rowspan="14" align="left" valign="top" colspan="1">Childhood cancer type<xref rid="cncr34561-note-0008" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Leukemia</td><td align="char" char="." valign="top" rowspan="1" colspan="1">259,372</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">31/14.8</td><td align="left" valign="top" rowspan="1" colspan="1">2.1 (1.5&#8211;3.0)</td><td align="left" valign="top" rowspan="1" colspan="1">1.0 (Ref)</td><td align="left" valign="top" rowspan="1" colspan="1">6.3 (3.2,12.3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hodgkin lymphoma</td><td align="char" char="." valign="top" rowspan="1" colspan="1">98,744</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">33/8.0</td><td align="left" valign="top" rowspan="1" colspan="1">4.1 (2.9&#8211;5.8)</td><td align="left" valign="top" rowspan="1" colspan="1">1.9 (1.1&#8211;3.3)</td><td align="left" valign="top" rowspan="1" colspan="1">25.3 (16.2&#8211;39.7)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Non&#8208;Hodgkin lymphoma</td><td align="char" char="." valign="top" rowspan="1" colspan="1">70,165</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">5/5.4</td><td align="left" valign="top" rowspan="1" colspan="1">0.9 (0.4&#8211;2.2)</td><td align="left" valign="top" rowspan="1" colspan="1">0.4 (0.2&#8211;1.1)</td><td align="left" valign="top" rowspan="1" colspan="1">0.0 (0.0&#8211;0.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CNS tumors</td><td align="char" char="." valign="top" rowspan="1" colspan="1">263,500</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">14/18.6</td><td align="left" valign="top" rowspan="1" colspan="1">0.8 (0.4&#8211;1.3)</td><td align="left" valign="top" rowspan="1" colspan="1">0.4 (0.2&#8211;0.7)</td><td align="left" valign="top" rowspan="1" colspan="1">0.0 (0.0&#8211;0.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Neuroblastoma</td><td align="char" char="." valign="top" rowspan="1" colspan="1">61,967</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">4/3.3</td><td align="left" valign="top" rowspan="1" colspan="1">1.2 (0.5&#8211;3.3)</td><td align="left" valign="top" rowspan="1" colspan="1">0.6 (0.2&#8211;1.8)</td><td align="left" valign="top" rowspan="1" colspan="1">1.2 (0.0&#8211;231.2)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Retinoblastoma</td><td align="char" char="." valign="top" rowspan="1" colspan="1">70,625</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">3/4.4</td><td align="left" valign="top" rowspan="1" colspan="1">0.7 (0.2&#8211;2.1)</td><td align="left" valign="top" rowspan="1" colspan="1">0.4 (0.1&#8211;1.3)</td><td align="left" valign="top" rowspan="1" colspan="1">0.0 (0.0&#8211;0.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Wilms tumor</td><td align="char" char="." valign="top" rowspan="1" colspan="1">109,314</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">14/6.2</td><td align="left" valign="top" rowspan="1" colspan="1">2.2 (1.3&#8211;3.8)</td><td align="left" valign="top" rowspan="1" colspan="1">1.2 (0.6&#8211;2.2)</td><td align="left" valign="top" rowspan="1" colspan="1">7.1 (2.8&#8211;18.3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Bone sarcoma</td><td align="char" char="." valign="top" rowspan="1" colspan="1">57,666</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">10/4.8</td><td align="left" valign="top" rowspan="1" colspan="1">2.1 (1.1&#8211;3.9)</td><td align="left" valign="top" rowspan="1" colspan="1">1.0 (0.4&#8211;2.1)</td><td align="left" valign="top" rowspan="1" colspan="1">9.1 (2.8&#8211;29.7)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Soft tissue sarcoma</td><td align="char" char="." valign="top" rowspan="1" colspan="1">93,042</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">4/6.8</td><td align="left" valign="top" rowspan="1" colspan="1">0.6 (0.2&#8211;1.6)</td><td align="left" valign="top" rowspan="1" colspan="1">0.3 (0.1&#8211;0.8)</td><td align="left" valign="top" rowspan="1" colspan="1">0.0 (0.0&#8211;0.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Thyroid carcinoma</td><td align="char" char="." valign="top" rowspan="1" colspan="1">23,535</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">4/1.8</td><td align="left" valign="top" rowspan="1" colspan="1">2.2 (0.8&#8211;5.9)</td><td align="left" valign="top" rowspan="1" colspan="1">1.1 (0.4&#8211;3.3)</td><td align="left" valign="top" rowspan="1" colspan="1">9.3 (1.5&#8211;55.9)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Gonadal</td><td align="char" char="." valign="top" rowspan="1" colspan="1">48,850</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">2/3.6</td><td align="left" valign="top" rowspan="1" colspan="1">0.6 (0.1&#8211;2.2)</td><td align="left" valign="top" rowspan="1" colspan="1">0.3 (0.1&#8211;1.2)</td><td align="left" valign="top" rowspan="1" colspan="1">0.0 (0.0&#8211;0.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Malignant melanoma</td><td align="char" char="." valign="top" rowspan="1" colspan="1">24,949</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">4/1.9</td><td align="left" valign="top" rowspan="1" colspan="1">2.1 (0.8&#8211;5.5)</td><td align="left" valign="top" rowspan="1" colspan="1">1.0 (0.3&#8211;3.0)</td><td align="left" valign="top" rowspan="1" colspan="1">8.3 (1.2&#8211;55.2)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Other</td><td align="char" char="." valign="top" rowspan="1" colspan="1">82,894</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">12/6.0</td><td align="left" valign="top" rowspan="1" colspan="1">2.0 (1.1&#8211;3.5)</td><td align="left" valign="top" rowspan="1" colspan="1">0.9 (0.5&#8211;1.9)</td><td align="left" valign="top" rowspan="1" colspan="1">7.2 (2.3&#8211;22.5)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> for heterogeneity</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&lt; .001</td><td align="left" valign="top" rowspan="1" colspan="1">&lt; .001</td><td align="left" valign="top" rowspan="1" colspan="1">&lt; .001</td></tr><tr><td rowspan="5" align="left" valign="top" colspan="1">Decade of childhood cancer diagnosis<xref rid="cncr34561-note-0008" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">&lt;1970</td><td align="char" char="." valign="top" rowspan="1" colspan="1">310,237</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">39/28.5</td><td align="left" valign="top" rowspan="1" colspan="1">1.4 (1.0&#8211;1.9)</td><td align="left" valign="top" rowspan="1" colspan="1">1.0 (Ref)</td><td align="left" valign="top" rowspan="1" colspan="1">3.4 (1.1&#8211;10.9)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">1970&#8211;1979</td><td align="char" char="." valign="top" rowspan="1" colspan="1">353,278</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">39/23.1</td><td align="left" valign="top" rowspan="1" colspan="1">1.7 (1.2&#8211;2.3)</td><td align="left" valign="top" rowspan="1" colspan="1">1.0 (0.6&#8211;1.6)</td><td align="left" valign="top" rowspan="1" colspan="1">4.5 (2.1&#8211;9.7)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">1980&#8211;1989</td><td align="char" char="." valign="top" rowspan="1" colspan="1">399,362</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">44/23.3</td><td align="left" valign="top" rowspan="1" colspan="1">1.9 (1.4&#8211;2.5)</td><td align="left" valign="top" rowspan="1" colspan="1">1.0 (0.6&#8211;1.8)</td><td align="left" valign="top" rowspan="1" colspan="1">5.2 (2.8&#8211;9.7)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">1990&#8211;2008</td><td align="char" char="." valign="top" rowspan="1" colspan="1">201,748</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">18/10.7</td><td align="left" valign="top" rowspan="1" colspan="1">1.7 (1.1&#8211;2.7)</td><td align="left" valign="top" rowspan="1" colspan="1">0.8 (0.4&#8211;1.5)</td><td align="left" valign="top" rowspan="1" colspan="1">3.6 (1.2&#8211;11.3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> for trend</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">.24</td><td align="left" valign="top" rowspan="1" colspan="1">.58</td><td align="left" valign="top" rowspan="1" colspan="1">.83</td></tr><tr><td rowspan="5" align="left" valign="top" colspan="1">Age at childhood cancer diagnosis, years<xref rid="cncr34561-note-0008" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Birth to 4</td><td align="char" char="." valign="top" rowspan="1" colspan="1">526,239</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">40/28.1</td><td align="left" valign="top" rowspan="1" colspan="1">1.4 (1.0&#8211;1.9)</td><td align="left" valign="top" rowspan="1" colspan="1">1.0 (Ref)</td><td align="left" valign="top" rowspan="1" colspan="1">2.3 (0.8&#8211;6.4)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">5&#8211;9</td><td align="char" char="." valign="top" rowspan="1" colspan="1">294,119</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">31/19.8</td><td align="left" valign="top" rowspan="1" colspan="1">1.6 (1.1&#8211;2.2)</td><td align="left" valign="top" rowspan="1" colspan="1">1.1 (0.7&#8211;1.9)</td><td align="left" valign="top" rowspan="1" colspan="1">3.8 (1.4&#8211;10.1)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">10&#8211;14</td><td align="char" char="." valign="top" rowspan="1" colspan="1">288,376</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">45/24.6</td><td align="left" valign="top" rowspan="1" colspan="1">1.8 (1.4&#8211;2.5)</td><td align="left" valign="top" rowspan="1" colspan="1">1.5 (0.8&#8211;2.5)</td><td align="left" valign="top" rowspan="1" colspan="1">7.1 (3.7&#8211;13.5)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">15&#8211;20</td><td align="char" char="." valign="top" rowspan="1" colspan="1">155,890</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">24/13.1</td><td align="left" valign="top" rowspan="1" colspan="1">1.8 (1.2&#8211;2.7)</td><td align="left" valign="top" rowspan="1" colspan="1">1.5 (0.8&#8211;3.0)</td><td align="left" valign="top" rowspan="1" colspan="1">7.0 (2.9&#8211;16.9)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> for trend</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">.22</td><td align="left" valign="top" rowspan="1" colspan="1">.15</td><td align="left" valign="top" rowspan="1" colspan="1">.04</td></tr><tr><td rowspan="6" align="left" valign="top" colspan="1">Attained age, years<xref rid="cncr34561-note-0008" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">&lt;20</td><td align="char" char="." valign="top" rowspan="1" colspan="1">410,373</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">35/13.3</td><td align="left" valign="top" rowspan="1" colspan="1">2.6 (1.9&#8211;3.7)</td><td align="left" valign="top" rowspan="1" colspan="1">1.0 (Ref)</td><td align="left" valign="top" rowspan="1" colspan="1">5.3 (3.1&#8211;9.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">20&#8211;29</td><td align="char" char="." valign="top" rowspan="1" colspan="1">419,216</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">39/26.1</td><td align="left" valign="top" rowspan="1" colspan="1">1.5 (1.1&#8211;2.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0.5 (0.3&#8211;0.8)</td><td align="left" valign="top" rowspan="1" colspan="1">3.1 (1.2&#8211;7.9)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">30&#8211;39</td><td align="char" char="." valign="top" rowspan="1" colspan="1">262,126</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">24/19.3</td><td align="left" valign="top" rowspan="1" colspan="1">1.2 (0.8&#8211;1.9)</td><td align="left" valign="top" rowspan="1" colspan="1">0.4 (0.2&#8211;0.6)</td><td align="left" valign="top" rowspan="1" colspan="1">1.8 (0.2&#8211;13.7)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">40&#8211;49</td><td align="char" char="." valign="top" rowspan="1" colspan="1">120,676</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">24/13.4</td><td align="left" valign="top" rowspan="1" colspan="1">1.8 (1.2&#8211;2.7)</td><td align="left" valign="top" rowspan="1" colspan="1">0.5 (0.3&#8211;1.0)</td><td align="left" valign="top" rowspan="1" colspan="1">8.7 (3.5&#8211;21.7)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8805;50</td><td align="char" char="." valign="top" rowspan="1" colspan="1">52,243</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">18/13.4</td><td align="left" valign="top" rowspan="1" colspan="1">1.3 (0.8&#8211;2.1)</td><td align="left" valign="top" rowspan="1" colspan="1">0.4 (0.2&#8211;0.9)</td><td align="left" valign="top" rowspan="1" colspan="1">8.7 (1.4&#8211;54.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> for trend</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">.02</td><td align="left" valign="top" rowspan="1" colspan="1">.01</td><td align="left" valign="top" rowspan="1" colspan="1">.59</td></tr><tr><td rowspan="5" align="left" valign="top" colspan="1">Follow&#8208;up time since 5&#8208;year survival, years<xref rid="cncr34561-note-0009" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">0&#8211;9</td><td align="char" char="." valign="top" rowspan="1" colspan="1">565,883</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">52/23.5</td><td align="left" valign="top" rowspan="1" colspan="1">2.2 (1.7&#8211;2.9)</td><td align="left" valign="top" rowspan="1" colspan="1">0.7 (0.4&#8211;1.0)</td><td align="left" valign="top" rowspan="1" colspan="1">5.0 (3.1&#8211;8.3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">10&#8211;19</td><td align="char" char="." valign="top" rowspan="1" colspan="1">370,881</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">36/23.6</td><td align="left" valign="top" rowspan="1" colspan="1">1.5 (1.1&#8211;2.1)</td><td align="left" valign="top" rowspan="1" colspan="1">0.6 (0.4&#8211;1.0)</td><td align="left" valign="top" rowspan="1" colspan="1">3.3 (1.3&#8211;8.6)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">20&#8211;29</td><td align="char" char="." valign="top" rowspan="1" colspan="1">212,289</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">27/18.2</td><td align="left" valign="top" rowspan="1" colspan="1">1.5 (1.0&#8211;2.2)</td><td align="left" valign="top" rowspan="1" colspan="1">0.6 (0.3&#8211;1.0)</td><td align="left" valign="top" rowspan="1" colspan="1">4.1 (1.3&#8211;13.2)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8805;30</td><td align="char" char="." valign="top" rowspan="1" colspan="1">115,571</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">25/20.2</td><td align="left" valign="top" rowspan="1" colspan="1">1.2 (0.8&#8211;1.8)</td><td align="left" valign="top" rowspan="1" colspan="1">0.7 (0.4&#8211;1.0)</td><td align="left" valign="top" rowspan="1" colspan="1">4.1 (0.5&#8211;32.1)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> for trend</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">.01</td><td align="left" valign="top" rowspan="1" colspan="1">.04</td><td align="left" valign="top" rowspan="1" colspan="1">.59</td></tr><tr><td rowspan="4" align="left" valign="top" colspan="1">Radiotherapy<xref rid="cncr34561-note-0010" ref-type="table-fn">
<sup>c</sup>
</xref>
<sup>,</sup>
<xref rid="cncr34561-note-0011" ref-type="table-fn">
<sup>d</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="char" char="." valign="top" rowspan="1" colspan="1">272,789</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">31/18.2</td><td align="left" valign="top" rowspan="1" colspan="1">1.7 (1.2&#8211;2.4)</td><td align="left" valign="top" rowspan="1" colspan="1">1.0 (Ref)</td><td align="left" valign="top" rowspan="1" colspan="1">4.7 (2.0&#8211;11.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="char" char="." valign="top" rowspan="1" colspan="1">478,392</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">59/33.9</td><td align="left" valign="top" rowspan="1" colspan="1">1.7 (1.3&#8211;2.2)</td><td align="left" valign="top" rowspan="1" colspan="1">1.1 (0.7&#8211;1.7)</td><td align="left" valign="top" rowspan="1" colspan="1">5.3 (2.9&#8211;9.6)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Missing</td><td align="char" char="." valign="top" rowspan="1" colspan="1">86,824</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">5/5.3</td><td align="left" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="left" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="left" valign="top" rowspan="1" colspan="1">&#8212;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> for heterogeneity</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">.92</td><td align="left" valign="top" rowspan="1" colspan="1">.63</td><td align="left" valign="top" rowspan="1" colspan="1">.83</td></tr><tr><td rowspan="4" align="left" valign="top" colspan="1">Chemotherapy<xref rid="cncr34561-note-0010" ref-type="table-fn">
<sup>c</sup>
</xref>
<sup>,</sup>
<xref rid="cncr34561-note-0011" ref-type="table-fn">
<sup>d</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="char" char="." valign="top" rowspan="1" colspan="1">275,213</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">29/23.0</td><td align="left" valign="top" rowspan="1" colspan="1">1.3 (0.9&#8211;1.8)</td><td align="left" valign="top" rowspan="1" colspan="1">1.0 (Ref)</td><td align="left" valign="top" rowspan="1" colspan="1">2.2 (0.4&#8211;12.6)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="char" char="." valign="top" rowspan="1" colspan="1">447,974</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">59/27.0</td><td align="left" valign="top" rowspan="1" colspan="1">2.2 (1.7&#8211;2.8)</td><td align="left" valign="top" rowspan="1" colspan="1">1.8 (1.1&#8211;2.9)</td><td align="left" valign="top" rowspan="1" colspan="1">7.1 (4.5&#8211;11.4)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Missing</td><td align="char" char="." valign="top" rowspan="1" colspan="1">114,818</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">7/7.4</td><td align="left" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="left" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="left" valign="top" rowspan="1" colspan="1">&#8212;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> for heterogeneity</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">.01</td><td align="left" valign="top" rowspan="1" colspan="1">.02</td><td align="left" valign="top" rowspan="1" colspan="1">.07</td></tr></tbody></table><table-wrap-foot id="cncr34561-ntgp-0002"><fn id="cncr34561-note-0007"><p>Abbreviations: 95% CI, 95% confidence interval; AER, absolute excess risk; CNS, central nervous system; Exp, expected; Obs, observed; Ref, reference category; RR, relative risk; SIR, standardized incidence ratio.</p></fn><fn id="cncr34561-note-0008"><label>
<sup>a</sup>
</label><p>RRs were derived from a model including sex, childhood cancer diagnosis, country, decade of childhood diagnosis, age at childhood diagnosis, and attained age.</p></fn><fn id="cncr34561-note-0009"><label>
<sup>b</sup>
</label><p>RRs were derived from a model including sex, childhood cancer diagnosis, country, decade of childhood diagnosis, age at childhood diagnosis, and follow&#8208;up time.</p></fn><fn id="cncr34561-note-0010"><label>
<sup>c</sup>
</label><p>RRs were derived from a model including sex, country, age at childhood diagnosis, attained age and treatment.</p></fn><fn id="cncr34561-note-0011"><label>
<sup>d</sup>
</label><p>Analyses relating to treatment included data from data providers that had &lt;30% of missing data (Nordic countries and Italian population&#8208;based cohort were excluded; treatment data were not available at all for Nordic countries).</p></fn></table-wrap-foot></table-wrap><fig position="float" fig-type="FIGURE" id="cncr34561-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Cumulative incidence of developing a subsequent primary lymphoma (all types) for types of childhood cancer with at least 20 observed lymphomas, as a function of attained age.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="CNCR-129-426-g001.jpg"/></fig></sec><sec id="cncr34561-sec-0100"><title>Risk of subsequent primary non&#8208;Hodgkin lymphoma</title><p>Overall, childhood cancer survivors were 2.3 times more likely to develop NHL than the general population (SIR, 2.3; 95% CI, 1.9&#8211;2.8), with five additional cases of NHL observed per 100,000 person&#8208;years (AER, 4.9; 95% CI, 3.5&#8211;6.9; Table&#160;<xref rid="cncr34561-tbl-0003" ref-type="table">3</xref>). Male and female childhood cancer survivors were at similar risk when adjusted for confounding factors (<italic toggle="yes">p</italic> for heterogeneity&#160;=&#160;.91). Survivors of HL and Wilms tumor were at greatest risk of developing NHL (SIR, 7.1 [95% CI, 5.1&#8211;10.0] and 3.1 [95% CI, 1.7&#8211;5.7], respectively), but the risk also was great for survivors of leukemia (SIR, 2.8; 95% CI, 1.8&#8211;4.4) and bone sarcoma (SIR, 2.7; 95% CI, 1.4&#8211;5.4).</p><table-wrap position="float" id="cncr34561-tbl-0003" content-type="TABLE" orientation="portrait"><label>TABLE 3</label><caption><p>Standardized incidence ratios, relative risks, and absolute excess risks, with 95% confidence intervals, for developing a subsequent primary non&#8208;Hodgkin lymphoma among a cohort of childhood cancer survivors (excluding non&#8208;Hodgkin lymphoma survivors)</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Factor</th><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="left" valign="bottom" rowspan="1" colspan="1">Obs/Exp</th><th align="left" valign="bottom" rowspan="1" colspan="1">SIR (95% CI)</th><th align="left" valign="bottom" rowspan="1" colspan="1">RR (95% CI)</th><th align="left" valign="bottom" rowspan="1" colspan="1">AER (95% CI)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Overall</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="char" char="/" valign="top" rowspan="1" colspan="1">104/45.0</td><td align="left" valign="top" rowspan="1" colspan="1">2.3 (1.9&#8211;2.8)</td><td align="left" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="left" valign="top" rowspan="1" colspan="1">4.9 (3.5&#8211;6.9)</td></tr><tr><td rowspan="3" align="left" valign="top" colspan="1">Sex<xref rid="cncr34561-note-0013" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Male</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">67/27.5</td><td align="left" valign="top" rowspan="1" colspan="1">2.4 (1.9&#8211;3.1)</td><td align="left" valign="top" rowspan="1" colspan="1">1.0 (Ref)</td><td align="left" valign="top" rowspan="1" colspan="1">6.3 (4.2&#8211;9.5)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Female</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">37/17.6</td><td align="left" valign="top" rowspan="1" colspan="1">2.1 (1.5&#8211;2.9)</td><td align="left" valign="top" rowspan="1" colspan="1">1.0 (0.6&#8211;1.5)</td><td align="left" valign="top" rowspan="1" colspan="1">3.4 (1.9&#8211;6.3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> for heterogeneity</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">.47</td><td align="left" valign="top" rowspan="1" colspan="1">.91</td><td align="left" valign="top" rowspan="1" colspan="1">.09</td></tr><tr><td rowspan="13" align="left" valign="top" colspan="1">Childhood cancer type<xref rid="cncr34561-note-0013" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Leukemia</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">19/6.8</td><td align="left" valign="top" rowspan="1" colspan="1">2.8 (1.8&#8211;4.4)</td><td align="left" valign="top" rowspan="1" colspan="1">1.0 (Ref)</td><td align="left" valign="top" rowspan="1" colspan="1">4.7 (2.3&#8211;9.5)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hodgkin lymphoma</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">33/4.6</td><td align="left" valign="top" rowspan="1" colspan="1">7.1 (5.1&#8211;10.0)</td><td align="left" valign="top" rowspan="1" colspan="1">3.2 (1.7&#8211;6.0)</td><td align="left" valign="top" rowspan="1" colspan="1">28.7 (19.3&#8211;42.7)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CNS tumors</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">9/10.8</td><td align="left" valign="top" rowspan="1" colspan="1">0.8 (0.4&#8211;1.6)</td><td align="left" valign="top" rowspan="1" colspan="1">0.4 (0.2&#8211;0.9)</td><td align="left" valign="top" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Neuroblastoma</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">3/1.7</td><td align="left" valign="top" rowspan="1" colspan="1">1.8 (0.6&#8211;5.6)</td><td align="left" valign="top" rowspan="1" colspan="1">0.8 (0.2&#8211;2.7)</td><td align="left" valign="top" rowspan="1" colspan="1">2.1 (0.2&#8211;27.6)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Retinoblastoma</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">2/2.6</td><td align="left" valign="top" rowspan="1" colspan="1">0.8 (0.2&#8211;3.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0.5 (0.1&#8211;2.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Wilms tumor</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">10/3.2</td><td align="left" valign="top" rowspan="1" colspan="1">3.1 (1.7&#8211;5.7)</td><td align="left" valign="top" rowspan="1" colspan="1">1.4 (0.6&#8211;3.2)</td><td align="left" valign="top" rowspan="1" colspan="1">6.2 (2.5&#8211;15.5)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Bone sarcoma</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">8/2.9</td><td align="left" valign="top" rowspan="1" colspan="1">2.7 (1.4&#8211;5.4)</td><td align="left" valign="top" rowspan="1" colspan="1">1.2 (0.5&#8211;3.1)</td><td align="left" valign="top" rowspan="1" colspan="1">8.8 (2.9&#8211;26.2)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Soft tissue sarcoma</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">2/4.1</td><td align="left" valign="top" rowspan="1" colspan="1">0.5 (0.1&#8211;2.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0.2 (0.1&#8211;1.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Thyroid carcinoma</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">3/1.2</td><td align="left" valign="top" rowspan="1" colspan="1">2.6 (0.8&#8211;8.1)</td><td align="left" valign="top" rowspan="1" colspan="1">1.3 (0.4&#8211;4.9)</td><td align="left" valign="top" rowspan="1" colspan="1">7.9 (1.3&#8211;49.3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Gonadal</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">2/2.2</td><td align="left" valign="top" rowspan="1" colspan="1">0.9 (0.2&#8211;3.7)</td><td align="left" valign="top" rowspan="1" colspan="1">0.4 (0.1&#8211;2.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Malignant melanoma</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">3/1.2</td><td align="left" valign="top" rowspan="1" colspan="1">2.4 (0.8&#8211;7.5)</td><td align="left" valign="top" rowspan="1" colspan="1">1.3 (0.4&#8211;4.7)</td><td align="left" valign="top" rowspan="1" colspan="1">7.1 (1.0&#8211;48.4)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Other</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">10/3.7</td><td align="left" valign="top" rowspan="1" colspan="1">2.7 (1.4&#8211;5.0)</td><td align="left" valign="top" rowspan="1" colspan="1">1.3 (0.6&#8211;3.1)</td><td align="left" valign="top" rowspan="1" colspan="1">7.6 (2.8&#8211;20.3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> for heterogeneity</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&lt; .001</td><td align="left" valign="top" rowspan="1" colspan="1">&lt; .001</td><td align="left" valign="top" rowspan="1" colspan="1">&lt; .001</td></tr><tr><td rowspan="5" align="left" valign="top" colspan="1">Decade of childhood cancer diagnosis<xref rid="cncr34561-note-0013" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">&lt;1970</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">28/19.5</td><td align="left" valign="top" rowspan="1" colspan="1">1.4 (1.0&#8211;2.1)</td><td align="left" valign="top" rowspan="1" colspan="1">1.0 (Ref)</td><td align="left" valign="top" rowspan="1" colspan="1">2.9 (0.8&#8211;9.7)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">1970&#8211;1979</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">30/12.2</td><td align="left" valign="top" rowspan="1" colspan="1">2.5 (1.7&#8211;3.5)</td><td align="left" valign="top" rowspan="1" colspan="1">1.3 (0.7&#8211;2.3)</td><td align="left" valign="top" rowspan="1" colspan="1">5.3 (2.9&#8211;9.7)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">1980&#8211;1989</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">33/9.7</td><td align="left" valign="top" rowspan="1" colspan="1">3.4 (2.4&#8211;4.8)</td><td align="left" valign="top" rowspan="1" colspan="1">1.5 (0.7&#8211;2.9)</td><td align="left" valign="top" rowspan="1" colspan="1">6.2 (3.9&#8211;10.1)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">1990&#8211;2008</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">13/3.7</td><td align="left" valign="top" rowspan="1" colspan="1">3.5 (2.1&#8211;6.1)</td><td align="left" valign="top" rowspan="1" colspan="1">1.1 (0.5&#8211;2.7)</td><td align="left" valign="top" rowspan="1" colspan="1">5.0 (2.3&#8211;10.7)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> for trend</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&lt; .001</td><td align="left" valign="top" rowspan="1" colspan="1">.64</td><td align="left" valign="top" rowspan="1" colspan="1">.58</td></tr><tr><td rowspan="5" align="left" valign="top" colspan="1">Age at childhood cancer diagnosis, years<xref rid="cncr34561-note-0013" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">0&#8211;3</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">27/13.9</td><td align="left" valign="top" rowspan="1" colspan="1">1.9 (1.3&#8211;2.8)</td><td align="left" valign="top" rowspan="1" colspan="1">1.0 (Ref)</td><td align="left" valign="top" rowspan="1" colspan="1">2.6 (1.2&#8211;5.6)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">4&#8211;7</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">21/9.7</td><td align="left" valign="top" rowspan="1" colspan="1">2.2 (1.4&#8211;3.3)</td><td align="left" valign="top" rowspan="1" colspan="1">1.1 (0.6&#8211;2.1)</td><td align="left" valign="top" rowspan="1" colspan="1">4.2 (1.9&#8211;9.3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">8&#8211;11</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">37/13.6</td><td align="left" valign="top" rowspan="1" colspan="1">2.7 (2.0&#8211;3.8)</td><td align="left" valign="top" rowspan="1" colspan="1">1.5 (0.8&#8211;2.9)</td><td align="left" valign="top" rowspan="1" colspan="1">8.8 (5.3&#8211;14.7)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">12&#8211;21</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">19/7.9</td><td align="left" valign="top" rowspan="1" colspan="1">2.4 (1.5&#8211;3.8)</td><td align="left" valign="top" rowspan="1" colspan="1">1.4 (0.6&#8211;3.4)</td><td align="left" valign="top" rowspan="1" colspan="1">7.5 (3.5&#8211;16.2)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> for trend</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">.59</td><td align="left" valign="top" rowspan="1" colspan="1">.28</td><td align="left" valign="top" rowspan="1" colspan="1">.03</td></tr><tr><td rowspan="6" align="left" valign="top" colspan="1">Attained age, years<xref rid="cncr34561-note-0013" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">&lt;20</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">23/4.9</td><td align="left" valign="top" rowspan="1" colspan="1">4.7 (3.1&#8211;7.1)</td><td align="left" valign="top" rowspan="1" colspan="1">1.0 (Ref)</td><td align="left" valign="top" rowspan="1" colspan="1">4.6 (2.8&#8211;7.8)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">20&#8211;29</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">27/8.5</td><td align="left" valign="top" rowspan="1" colspan="1">3.2 (2.2&#8211;4.6)</td><td align="left" valign="top" rowspan="1" colspan="1">0.5 (0.3&#8211;1.0)</td><td align="left" valign="top" rowspan="1" colspan="1">4.7 (2.7&#8211;8.2)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">30&#8211;39</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">16/10.2</td><td align="left" valign="top" rowspan="1" colspan="1">1.6 (1.0&#8211;2.6)</td><td align="left" valign="top" rowspan="1" colspan="1">0.3 (0.1&#8211;0.5)</td><td align="left" valign="top" rowspan="1" colspan="1">2.4 (0.6&#8211;9.1)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">40&#8211;49</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">20/1</td><td align="left" valign="top" rowspan="1" colspan="1">2.0 (1.3&#8211;3.1)</td><td align="left" valign="top" rowspan="1" colspan="1">0.4 (0.2&#8211;0.8)</td><td align="left" valign="top" rowspan="1" colspan="1">8.7 (3.6&#8211;21.1)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8805;50</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">18/11.5</td><td align="left" valign="top" rowspan="1" colspan="1">1.6 (1.0&#8211;2.5)</td><td align="left" valign="top" rowspan="1" colspan="1">0.3 (0.1&#8211;0.8)</td><td align="left" valign="top" rowspan="1" colspan="1">13.3 (3.7&#8211;47.6)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> for trend</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&lt; .001</td><td align="left" valign="top" rowspan="1" colspan="1">&lt; .001</td><td align="left" valign="top" rowspan="1" colspan="1">.39</td></tr><tr><td rowspan="5" align="left" valign="top" colspan="1">Follow&#8208;up time since 5&#8208;year survival, years<xref rid="cncr34561-note-0014" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">0&#8211;9</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">36/8.1</td><td align="left" valign="top" rowspan="1" colspan="1">4.4 (3.2&#8211;6.1)</td><td align="left" valign="top" rowspan="1" colspan="1">1.0 (Ref)</td><td align="left" valign="top" rowspan="1" colspan="1">5.2 (3.4&#8211;8.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">10&#8211;19</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">25/9.5</td><td align="left" valign="top" rowspan="1" colspan="1">2.6 (1.8&#8211;3.9)</td><td align="left" valign="top" rowspan="1" colspan="1">0.6 (0.3&#8211;1.0)</td><td align="left" valign="top" rowspan="1" colspan="1">4.4 (2.4&#8211;8.3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">20&#8211;29</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">20/11.0</td><td align="left" valign="top" rowspan="1" colspan="1">1.8 (1.2&#8211;2.8)</td><td align="left" valign="top" rowspan="1" colspan="1">0.4 (0.2&#8211;0.8)</td><td align="left" valign="top" rowspan="1" colspan="1">4.5 (1.7&#8211;11.8)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8805;30</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">23/16.4</td><td align="left" valign="top" rowspan="1" colspan="1">1.4 (0.9&#8211;2.1)</td><td align="left" valign="top" rowspan="1" colspan="1">0.4 (0.2&#8211;0.8)</td><td align="left" valign="top" rowspan="1" colspan="1">6.0 (1.4&#8211;25.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> for trend</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&lt; .001</td><td align="left" valign="top" rowspan="1" colspan="1">&lt; .001</td><td align="left" valign="top" rowspan="1" colspan="1">.82</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Radiotherapy<xref rid="cncr34561-note-0015" ref-type="table-fn">
<sup>c</sup>
</xref>
<sup>,</sup>
<xref rid="cncr34561-note-0016" ref-type="table-fn">
<sup>d</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">21/9.5</td><td align="left" valign="top" rowspan="1" colspan="1">2.2 (1.4&#8211;3.4)</td><td align="left" valign="top" rowspan="1" colspan="1">1.0 (Ref)</td><td align="left" valign="top" rowspan="1" colspan="1">4.5 (2.1&#8211;9.8)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">48/18.1</td><td align="left" valign="top" rowspan="1" colspan="1">2.7 (2.0&#8211;3.5)</td><td align="left" valign="top" rowspan="1" colspan="1">1.2 (0.7&#8211;2.0)</td><td align="left" valign="top" rowspan="1" colspan="1">6.6 (4.2&#8211;10.4)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Missing</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">5/2.3</td><td align="left" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="left" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="left" valign="top" rowspan="1" colspan="1">&#8212;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> for heterogeneity</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">.48</td><td align="left" valign="top" rowspan="1" colspan="1">.32</td><td align="left" valign="top" rowspan="1" colspan="1">.38</td></tr><tr><td rowspan="4" align="left" valign="top" colspan="1">Chemotherapy<xref rid="cncr34561-note-0015" ref-type="table-fn">
<sup>c</sup>
</xref>
<sup>,</sup>
<xref rid="cncr34561-note-0016" ref-type="table-fn">
<sup>d</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">22/14.3</td><td align="left" valign="top" rowspan="1" colspan="1">1.5 (1.0&#8211;2.3)</td><td align="left" valign="top" rowspan="1" colspan="1">1.0 (Ref)</td><td align="left" valign="top" rowspan="1" colspan="1">2.9 (0.9&#8211;9.5)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">46/12.1</td><td align="left" valign="top" rowspan="1" colspan="1">3.8 (2.8&#8211;5.1)</td><td align="left" valign="top" rowspan="1" colspan="1">2.1 (1.2&#8211;3.9)</td><td align="left" valign="top" rowspan="1" colspan="1">8.2 (5.5&#8211;12.1)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Missing</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">6/3.6</td><td align="left" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="left" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="left" valign="top" rowspan="1" colspan="1">&#8212;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> for heterogeneity</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&lt; .001</td><td align="left" valign="top" rowspan="1" colspan="1">.01</td><td align="left" valign="top" rowspan="1" colspan="1">.04</td></tr></tbody></table><table-wrap-foot id="cncr34561-ntgp-0003"><fn id="cncr34561-note-0012"><p>Abbreviations: 95% CI, 95% confidence interval; AER, absolute excess risk; CNS, central nervous system; Exp, expected; Obs, observed; Ref, reference category; RR, relative risk; SIR, standardized incidence ratio.</p></fn><fn id="cncr34561-note-0013"><label>
<sup>a</sup>
</label><p>RRs were derived from a model including sex, childhood cancer diagnosis, country, decade of childhood diagnosis, age at childhood diagnosis, and attained age.</p></fn><fn id="cncr34561-note-0014"><label>
<sup>b</sup>
</label><p>RRs were derived from a model including sex, childhood cancer diagnosis, country, decade of childhood diagnosis, age at childhood diagnosis, and follow&#8208;up time.</p></fn><fn id="cncr34561-note-0015"><label>
<sup>c</sup>
</label><p>RRs were derived from a model including sex, country, age at childhood diagnosis, attained age, and treatment.</p></fn><fn id="cncr34561-note-0016"><label>
<sup>d</sup>
</label><p>Analyses relating to treatment included data from data providers that had &lt;30% of missing data (Nordic countries and Italian population&#8208;based cohorts were excluded; treatment data were not available at all for Nordic countries).</p></fn></table-wrap-foot></table-wrap><p>More recent decades of childhood cancer diagnosis showed an increase in the SIRs of developing NHL (<italic toggle="yes">p</italic> for trend &lt; .001), but this effect was not apparent after adjustment for confounders (<italic toggle="yes">p</italic> for trend&#160;=&#160;.64), particularly attained age. Increasing attained age and follow&#8208;up time demonstrated a decreasing trend in the SIRs of developing NHL (Table&#160;<xref rid="cncr34561-tbl-0003" ref-type="table">3</xref>; <italic toggle="yes">p</italic> for trend &lt; .001). There was a significantly increased risk of developing NHL among survivors who had received chemotherapy for any childhood cancer (RR, 2.1; 95% CI, 1.2&#8211;3.9). However, the RR was not significantly increased for survivors who had received radiotherapy for any childhood cancer (RR, 1.2; 95% CI, 0.7&#8211;2.0). The cumulative incidence of developing NHL after HL was 1.6% (95% CI, 0.7%&#8211;3.1%) by age 65&#160;years (Figure&#160;<xref rid="cncr34561-fig-0001" ref-type="fig">1</xref>; all SPLs after HL were NHLs).</p></sec><sec id="cncr34561-sec-0110"><title>Risk of subsequent primary Hodgkin lymphoma</title><p>Overall, childhood cancer survivors were no more likely to develop HL compared with the general population (SIR, 1.1; 95% CI, 0.8&#8211;1.5; Table&#160;<xref rid="cncr34561-tbl-0004" ref-type="table">4</xref>). A childhood cancer diagnosis of NHL conferred an increased risk of developing HL relative to the general population (SIR, 2.4; 95% CI, 1.0&#8211;5.9). This was not observed following other types of childhood cancer. The SIR for HL did not vary by decade of diagnosis (<italic toggle="yes">p</italic> for trend&#160;=&#160;.21), age at diagnosis (<italic toggle="yes">p</italic>&#160;=&#160;.97), or with attained age (<italic toggle="yes">p</italic> for trend&#160;=&#160;.24), although multivariable analyses suggested that the RRs were lower in those diagnosed in more recent decades (<italic toggle="yes">p</italic> for trend&#160;=&#160;.03).</p><table-wrap position="float" id="cncr34561-tbl-0004" content-type="TABLE" orientation="portrait"><label>TABLE 4</label><caption><p>Standardized incidence ratios, relative risks, and absolute excess risks, with 95% confidence intervals, for developing a subsequent primary Hodgkin lymphoma among a cohort of childhood cancer survivors (excluding Hodgkin lymphoma survivors)</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Factor</th><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="left" valign="bottom" rowspan="1" colspan="1">Obs/Exp</th><th align="left" valign="bottom" rowspan="1" colspan="1">SIR (95% CI)</th><th align="left" valign="bottom" rowspan="1" colspan="1">RR (95% CI)<xref rid="cncr34561-note-0019" ref-type="table-fn">
<sup>b</sup>
</xref>
</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Overall</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="char" char="/" valign="top" rowspan="1" colspan="1">36/34.2</td><td align="left" valign="top" rowspan="1" colspan="1">1.1 (0.8&#8211;1.5)</td><td align="left" valign="top" rowspan="1" colspan="1">&#8208;</td></tr><tr><td rowspan="3" align="left" valign="top" colspan="1">Sex</td><td align="left" valign="top" rowspan="1" colspan="1">Males</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">26/19.4</td><td align="left" valign="top" rowspan="1" colspan="1">1.3 (0.9&#8211;2.0)</td><td align="left" valign="top" rowspan="1" colspan="1">1.0 (ref.)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Females</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">10/14.7</td><td align="left" valign="top" rowspan="1" colspan="1">0.7 (0.4&#8211;1.3)</td><td align="left" valign="top" rowspan="1" colspan="1">0.5 (0.3&#8211;1.1)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> for heterogeneity</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">.06</td><td align="left" valign="top" rowspan="1" colspan="1">.09</td></tr><tr><td rowspan="5" align="left" valign="top" colspan="1">Childhood cancer diagnosis</td><td align="left" valign="top" rowspan="1" colspan="1">Leukemia</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">12/8.0</td><td align="left" valign="top" rowspan="1" colspan="1">1.5 (0.9&#8211;2.6)</td><td align="left" valign="top" rowspan="1" colspan="1">1.0 (Ref)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Non&#8208;Hodgkin lymphoma</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">5/2.0</td><td align="left" valign="top" rowspan="1" colspan="1">2.4 (1.0&#8211;5.9)</td><td align="left" valign="top" rowspan="1" colspan="1">1.2 (0.4&#8211;3.7)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CNS tumors</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">5/7.8</td><td align="left" valign="top" rowspan="1" colspan="1">0.6 (0.3&#8211;1.5)</td><td align="left" valign="top" rowspan="1" colspan="1">0.3 (0.1&#8211;0.9)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Other<xref rid="cncr34561-note-0020" ref-type="table-fn">
<sup>c</sup>
</xref>
</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">14/16.3</td><td align="left" valign="top" rowspan="1" colspan="1">0.9 (0.5&#8211;1.4)</td><td align="left" valign="top" rowspan="1" colspan="1">0.3 (0.1&#8211;0.8)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> for heterogeneity</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">.19</td><td align="left" valign="top" rowspan="1" colspan="1">.02</td></tr><tr><td rowspan="5" align="left" valign="top" colspan="1">Decade of childhood cancer diagnosis</td><td align="left" valign="top" rowspan="1" colspan="1">&lt;1970</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">11/7.3</td><td align="left" valign="top" rowspan="1" colspan="1">1.5 (0.8&#8211;2.7)</td><td align="left" valign="top" rowspan="1" colspan="1">1.0 (Ref)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">1970&#8211;1979</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">9/9.2</td><td align="left" valign="top" rowspan="1" colspan="1">1.0 (0.5&#8211;1.9)</td><td align="left" valign="top" rowspan="1" colspan="1">0.4 (0.2&#8211;1.1)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">1980&#8211;1989</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">11/11.8</td><td align="left" valign="top" rowspan="1" colspan="1">0.9 (0.5&#8211;1.7)</td><td align="left" valign="top" rowspan="1" colspan="1">0.4 (0.1&#8211;0.9)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">1990&#8211;2008</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">5/5.9</td><td align="left" valign="top" rowspan="1" colspan="1">0.8 (0.4&#8211;&#8211;2.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0.3 (0.1&#8211;0.9)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> for trend</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">.23</td><td align="left" valign="top" rowspan="1" colspan="1">.03</td></tr><tr><td rowspan="5" align="left" valign="top" colspan="1">Age at childhood cancer diagnosis, years</td><td align="left" valign="top" rowspan="1" colspan="1">Birth to 3</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">13/13.6</td><td align="left" valign="top" rowspan="1" colspan="1">1.0 (0.6&#8211;1.6)</td><td align="left" valign="top" rowspan="1" colspan="1">1.0 (Ref)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">4&#8211;7</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">10/8.5</td><td align="left" valign="top" rowspan="1" colspan="1">1.2 (0.6&#8211;2.2)</td><td align="left" valign="top" rowspan="1" colspan="1">1.2 (0.5&#8211;2.9)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">8&#8211;11</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">8/8.1</td><td align="left" valign="top" rowspan="1" colspan="1">1.0 (0.5&#8211;2.0)</td><td align="left" valign="top" rowspan="1" colspan="1">1.2 (0.5&#8211;3.2)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">12&#8211;21</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">5/3.9</td><td align="left" valign="top" rowspan="1" colspan="1">1.3 (0.5&#8211;3.1)</td><td align="left" valign="top" rowspan="1" colspan="1">2.0 (0.7&#8211;6.3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> for trend</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">.69</td><td align="left" valign="top" rowspan="1" colspan="1">.29</td></tr><tr><td rowspan="6" align="left" valign="top" colspan="1">Attained age, years</td><td align="left" valign="top" rowspan="1" colspan="1">&lt;20</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">12/7.8</td><td align="left" valign="top" rowspan="1" colspan="1">1.5 (0.9&#8211;2.7)</td><td align="left" valign="top" rowspan="1" colspan="1">1.0 (Ref)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">20&#8211;29</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">12/15.4</td><td align="left" valign="top" rowspan="1" colspan="1">0.8 (0.4&#8211;1.4)</td><td align="left" valign="top" rowspan="1" colspan="1">0.4 (0.2&#8211;1.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">30&#8211;39</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">8/7.5</td><td align="left" valign="top" rowspan="1" colspan="1">1.1 (0.5&#8211;2.1)</td><td align="left" valign="top" rowspan="1" colspan="1">0.5 (0.2&#8211;1.3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">40&#8211;49</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">4/2.5</td><td align="left" valign="top" rowspan="1" colspan="1">1.6 (0.6&#8211;4.3)</td><td align="left" valign="top" rowspan="1" colspan="1">0.7 (0.2&#8211;2.3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8805;50</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">0/1.0</td><td align="left" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="left" valign="top" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> for trend</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">.31</td><td align="left" valign="top" rowspan="1" colspan="1">.09</td></tr><tr><td rowspan="5" align="left" valign="top" colspan="1">Follow&#8208;up time since 5&#8208;year survival, years<xref rid="cncr34561-note-0018" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">0&#8211;9</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">16/13.1</td><td align="left" valign="top" rowspan="1" colspan="1">1.2 (0.7&#8211;2.0)</td><td align="left" valign="top" rowspan="1" colspan="1">1.0 (Ref)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">10&#8211;19</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">11/12.5</td><td align="left" valign="top" rowspan="1" colspan="1">0.9 (0.5&#8211;1.6)</td><td align="left" valign="top" rowspan="1" colspan="1">0.4 (0.2&#8211;0.9)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">20&#8211;29</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">7/6.1</td><td align="left" valign="top" rowspan="1" colspan="1">1.2 (0.6&#8211;2.4)</td><td align="left" valign="top" rowspan="1" colspan="1">0.5 (0.2&#8211;1.2)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8805;30</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">2/2.6</td><td align="left" valign="top" rowspan="1" colspan="1">0.8 (0.2&#8211;3.1)</td><td align="left" valign="top" rowspan="1" colspan="1">0.6 (0.2&#8211;2.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> for trend</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">.58</td><td align="left" valign="top" rowspan="1" colspan="1">.05</td></tr><tr><td rowspan="4" align="left" valign="top" colspan="1">Radiotherapy<xref rid="cncr34561-note-0020" ref-type="table-fn">
<sup>c</sup>
</xref>
<sup>,</sup>
<xref rid="cncr34561-note-0021" ref-type="table-fn">
<sup>d</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">10/7.7</td><td align="left" valign="top" rowspan="1" colspan="1">1.3 (0.7&#8211;2.4)</td><td align="left" valign="top" rowspan="1" colspan="1">1.0 (Ref)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">11/12.9</td><td align="left" valign="top" rowspan="1" colspan="1">0.9 (0.5&#8211;1.5)</td><td align="left" valign="top" rowspan="1" colspan="1">0.8 (0.3&#8211;2.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Missing</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">0/2.4</td><td align="left" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="left" valign="top" rowspan="1" colspan="1">&#8212;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> for heterogeneity</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">.34</td><td align="left" valign="top" rowspan="1" colspan="1">.71</td></tr><tr><td rowspan="4" align="left" valign="top" colspan="1">Chemotherapy<xref rid="cncr34561-note-0020" ref-type="table-fn">
<sup>c</sup>
</xref>
<sup>,</sup>
<xref rid="cncr34561-note-0021" ref-type="table-fn">
<sup>d</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">7/7.3</td><td align="left" valign="top" rowspan="1" colspan="1">1.0 (0.5&#8211;2.0)</td><td align="left" valign="top" rowspan="1" colspan="1">1.0 (Ref)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">13/12.6</td><td align="left" valign="top" rowspan="1" colspan="1">1.0 (0.6&#8211;1.8)</td><td align="left" valign="top" rowspan="1" colspan="1">1.1 (0.4&#8211;2.9)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Missing</td><td align="char" char="/" valign="top" rowspan="1" colspan="1">1/3.2</td><td align="left" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="left" valign="top" rowspan="1" colspan="1">&#8212;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> for heterogeneity</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">.87</td><td align="left" valign="top" rowspan="1" colspan="1">.79</td></tr></tbody></table><table-wrap-foot id="cncr34561-ntgp-0004"><fn id="cncr34561-note-0017"><p>Abbreviations: 95% CI, 95% confidence interval; CNS, central nervous system; Exp, expected; Obs, observed; Ref, reference category; RR, relative risk; SIR, standardized incidence ratio.</p></fn><fn id="cncr34561-note-0018"><label>
<sup>a</sup>
</label><p>RRs were derived from a model including sex, childhood cancer diagnosis, country, decade of childhood diagnosis, age at childhood diagnosis, and attained age.</p></fn><fn id="cncr34561-note-0019"><label>
<sup>b</sup>
</label><p>RRs were derived from a model including sex, childhood cancer diagnosis, country, decade of childhood diagnosis, age at childhood diagnosis, and follow&#8208;up time.</p></fn><fn id="cncr34561-note-0020"><label>
<sup>c</sup>
</label><p>RRs were derived from a model including sex, country, age at childhood diagnosis, attained age and treatment.</p></fn><fn id="cncr34561-note-0021"><label>
<sup>d</sup>
</label><p>Analyses relating to treatment included data from data providers that had &lt;30% of missing data (Nordic countries and Italian population&#8208;based cohorts were excluded; treatment data were not available at all for Nordic countries).</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="cncr34561-sec-0120"><title>DISCUSSION</title><sec id="cncr34561-sec-0130"><title>Main findings</title><p>To our knowledge, this is by far the largest cohort study analyzing the risk of SPLs in childhood cancer survivors and, for the first time within a large&#8208;scale study, the risks of NHL and HL individually. Novel findings include that childhood cancer survivors are 2.3 times more likely to develop NHL than the general population, with survivors of HL, Wilms tumor, leukemia, and bone sarcoma at greatest risk. Conversely, the risk of HL among childhood cancer survivors is not increased, except in survivors of NHL. This study has further found that childhood cancer survivors who have received chemotherapy are almost twice as likely to develop a subsequent primary NHL than survivors treated without chemotherapy. This increase in risk, however, does not extend to survivors who received radiotherapy for any childhood cancer.</p></sec><sec id="cncr34561-sec-0140"><title>Previous studies</title><p>When evaluating the overall risk of childhood cancer survivors developing SPLs, the SIR of 1.6 for total lymphoma found in this analysis was consistent with the results of the North American Childhood Cancer Survivor Study conducted in a cohort of 14,359 childhood cancer survivors (SIR, 1.6; 95% CI, 1.2&#8211;2.1).<xref rid="cncr34561-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> In that North American study, the SIR beyond age 40&#160;years was still increased 2.6&#8208;fold (95% CI, 1.5&#8211;5.6); however, in our data, the risk was not increased beyond age 50 years (SIR, 1.3; 95% CI, 0.8&#8211;2.1),<xref rid="cncr34561-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> although overlapping confidence intervals suggest that these SIRs are not necessarily inconsistent. There have been suggestions that, for the generality of survivors, historic treatment regimens across North America may have been more aggressive than across Europe, which may translate into a higher risk of long&#8208;term complications of treatment, including subsequent primary malignancies.<xref rid="cncr34561-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref> Other studies documenting the risk of developing SPLs derived their data from European cohorts (Nordic countries and the Netherlands, respectively), which also contributed to the current PanCareSurFup cohort. Consistent with our findings, the Nordic study reported a moderately increased risk for bone marrow and lymphatic system malignancies, although this includes a wider range of diagnoses and thus is less valid to interpret for SPL alone (SIR, 2.6; 95% CI, 2.2&#8211;3.2).<xref rid="cncr34561-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> A Dutch study among 6165 childhood cancer survivors quoted a slightly higher, but not inconsistent, risk of NHL (SIR, 3.9; 95% CI, 2.0&#8211;7.0).<xref rid="cncr34561-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> Furthermore, the Dutch study observed only six cases of HL and, as a result, reported a lower and insignificant risk of HL (SIR, 1.9; 95% CI, 0.7&#8211;4.1), which supports our finding that childhood cancer survivors are no more likely to develop HL than the general population.</p><p>Although very few studies have investigated the risk of NHL among the generality of childhood cancer survivors, several studies have reported increased risks of NHL after (mostly) adult HL, with a wide range in SIRs from 3.0 to 32.0, which is not inconsistent with the SIR of 7.1 found in the current analysis.<xref rid="cncr34561-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>, <xref rid="cncr34561-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="cncr34561-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="cncr34561-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="cncr34561-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>, <xref rid="cncr34561-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>, <xref rid="cncr34561-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>, <xref rid="cncr34561-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> Postulated risks factors include immunodeficiency, because Zarate&#8208;Osorno et&#160;al.<xref rid="cncr34561-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref> concluded that the types of NHL diagnosed among patients with HL were clinically, histologically, and immunophenotypically similar to that found in immunosuppressed patients. Here, we found that survivors who received chemotherapy were at the highest risk. Whether any specific chemotherapeutic agent or whether chemotherapy&#8208;induced immunosuppression may be implicated in the development of NHL, however, is not clear. Swerdlow et&#160;al<xref rid="cncr34561-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> found increased risks of NHL among HL survivors after various different chemotherapy regimens, suggesting that not one specific chemotherapy agent is implicated. We also found increased risks of NHL among survivors of Wilms tumor, leukemia, and bone sarcoma who likely have received different chemotherapy regimens. Exposure to prolonged chemotherapy has been shown to be immunosuppressive and thus may create an environment in which latent oncogenic viruses, such as Epstein&#8211;Barr virus, that have been associated with NHL development may be reactivated.<xref rid="cncr34561-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref>, <xref rid="cncr34561-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref> Among (bilateral) Wilms tumor survivors, the increased risk may to some extent also be related to immunosuppressive therapy for a kidney transplant, which could cause posttransplantation lymphoproliferative disorders,<xref rid="cncr34561-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref> including NHL, although typically this occurs in the first few years after kidney transplantation, with a potential second peak 7&#8211;10&#160;years later.<xref rid="cncr34561-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref> However, in our data, all Wilms tumor survivors who developed NHL had unilateral Wilms tumor; and, for 9 of 10 Wilms tumor survivors who developed NHL, this occurred at least 13&#160;years after the original Wilms tumor diagnosis (range, 6&#8211;53&#160;years), suggesting that this is probably an unlikely explanation. Similarly, stem cell transplantation among leukemia survivors may have increased the risk of posttransplantation lymphoproliferative disorders, including NHL; but, in our cohort, only one leukemia survivor with NHL had undergone stem cell transplantation. Further studies evaluating detailed treatment factors and the role of specific chemotherapy exposures in relation to immunosuppression and Epstein&#8211;Barr virus infection status are warranted.</p><p>In the current study, there was no indication of any significant difference in the risk of SPL between those who received radiotherapy only during childhood and those who did not. This is consistent with research conducted in individuals who were exposed to radiation after the atomic bomb, in whom no increased risk was observed either.<xref rid="cncr34561-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref>
</p></sec><sec id="cncr34561-sec-0150"><title>Clinical implications</title><p>Current guidelines from the Children's Oncology Group for the long&#8208;term surveillance of childhood cancer survivors do not include details of an increased SPL risk.<xref rid="cncr34561-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref> Although we do not advocate surveillance of survivors because the absolute risks are small, survivors of HL, Wilms tumor, leukemia, and bone sarcoma should be encouraged to seek clinical advice from a medical professional if potentially relevant symptoms of NHL develop, including swellings, fever, and night sweats. Previous studies identified HL survivors to be at risk of NHL, but here we found that survivors of Wilms tumor, leukemia, and bone sarcoma are also at risk; it would be important for health care professionals responsible for the long&#8208;term follow&#8208;up of these survivors to be aware of the increased risk. Finally, it may be worth emphasizing to survivors that treatment with radiotherapy does not seem to suggest an increased risk of SPLs.</p></sec><sec id="cncr34561-sec-0160"><title>Study limitations</title><p>One of the potential limitations of this study is the lack of detailed data concerning childhood treatment variables, such as cumulative doses of radiotherapy (including radiotherapy field) and chemotherapy. To fully assess the effect of treatment modalities on SPL risk, it would be beneficial to perform further analysis in the form of a nested case&#8211;control study in which detailed treatment information would be collected so that the risk of developing an SPL by cumulative doses of both radiation and chemotherapy agents can be calculated.</p><p>Another potential limitation of the study is the relatively small number of subsequent primary HLs observed, meaning that some components of the study may lack statistical power for further detailed analyses. That said, with more than three times the number of SPLs compared with the next largest study, this study is the largest cohort of childhood cancer survivors with subsequent HLs to date and hence provides the most accurate estimates of these risks.<xref rid="cncr34561-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>
</p><p>Furthermore, it is feasible that, in some instances, the first primary lymphoma was misdiagnosed as HL instead of NHL.<xref rid="cncr34561-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> In such cases, the subsequent primary NHL would not have been a true subsequent primary and thus resulted in an overestimate of the risk of developing NHL after HL. Although we cannot investigate the extent to which such misclassification has occurred, in a German study among adult patients with HL (aged 19&#8211;71&#160;years), misclassification of the first primary lymphoma as HL instead of NHL occurred only for 2.1% of patients, suggesting that the extent to which potential misclassification might affect our results is likely minimal.<xref rid="cncr34561-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> Also, we observed increased risks of NHL in survivors of Wilms tumor, leukemia, and bone sarcoma, suggesting that there is a critical role of treatment or immunodeficiency in the development of NHL after childhood cancer, and the increase cannot be caused only by misclassification of the first primary cancer.</p><p>Another potential limitation relates to heterogeneity in subtypes of subsequent primary NHL, with each subtype potentially having a different etiology. An investigation of treatment&#8208;related risk factors for subtypes of NHL is simply not feasible within this large&#8208;scale cohort study and would require a case&#8211;control study.</p></sec></sec><sec id="cncr34561-sec-0170"><title>CONCLUSION</title><p>In conclusion, in this largest cohort study to date, we demonstrate that the risk of developing NHL was increased particularly among those surviving HL, Wilms tumor, leukemia, and bone sarcoma and those who were treated with chemotherapy for any cancer. Only NHL survivors were at increased risk of HL. Although, for most childhood cancer survivors, the absolute risk of developing an SPL is low, health care professionals should be aware of the increased risk of developing NHL among survivors of HL, Wilms tumor, leukemia and bone sarcoma and in any survivors treated with chemotherapy. Survivors should be encouraged to seek clinical advice from a medical professional if potentially relevant symptoms of NHL develop, including swellings, fever, and night sweats.</p></sec><sec id="cncr34561-sec-0180"><title>AUTHOR CONTRIBUTIONS</title><p>Statistical analysis: <bold>Isabelle M. Dudley</bold>, <bold>Raoul C. Reulen</bold>, <bold>Michael M. Hawkins</bold>, <bold>David L. Winter</bold>, and <bold>Ceren Sunguc</bold>; initial drafting of the article: <bold>Isabelle M. Dudley</bold>, <bold>Raoul C. Reulen</bold>, and <bold>Michael M. Hawkins</bold>; study design and concept: <bold>Raoul C. Reulen</bold>, <bold>Michael M. Hawkins</bold>, <bold>Leontien C. Kremer</bold>, <bold>Florent de Vathaire</bold>, <bold>Lars Hjorth</bold>, <bold>Roderick Skinner</bold>, <bold>Riccardo Haupt</bold>, and <bold>Jop C. Teepen</bold>; data provider lead: <bold>Jeanette F. Winther</bold>, <bold>Lars Hjorth</bold>, <bold>Thorgerdur Gudmundsdottir</bold>, <bold>Maria Winther Gunnes</bold>, <bold>P&#228;ivi M. L&#228;hteenm&#228;ki</bold>, <bold>Lorna Zadravec Zaletel</bold>, <bold>Riccardo Haupt</bold>, <bold>Monica Terenziani</bold>, <bold>Florent de Vathaire</bold>, <bold>Leontien C. Kremer</bold>, <bold>Claudia E. Kuehni</bold>, <bold>Zsuzsanna Jakab</bold>, and <bold>Stanislaw Garwicz</bold>; data curation: <bold>Raoul C. Reulen</bold>, <bold>David L. Winter</bold>, <bold>Desiree Grabow</bold>, <bold>Melanie Kaiser</bold>, and <bold>Peter Kaatsch</bold>; interpretation of data and critically revising of the article: all authors; all authors contributed to final review and editing.</p></sec><sec sec-type="COI-statement" id="cncr34561-sec-0200"><title>CONFLICTS OF INTEREST</title><p>Zsuzsanna Jakab reports personal fees from Semmelweis Egyetem outside the submitted work. Lars Hjorth reports personal fees from Bayer and F. Hoffmann&#8208;La Roche outside the submitted work. The remaining authors made no disclosures.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="cncr34561-sup-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information S1</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CNCR-129-426-s001.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="cncr34561-sec-0190"><title>ACKNOWLEDGMENTS</title><p>The authors are very grateful to the childhood cancer survivors whose information was used in this data set. The authors thank the following individuals from each country for their contribution to data preparation: <italic toggle="yes">France:</italic> Angela Jackson, Florent Dayet, Amar Kahlouche, Fara Diop, Sylvie Challeton, Martine Labb&#233;, and Isao Kobayashi; <italic toggle="yes">Italy:</italic> the Italian Association of Pediatric Hematology and Oncology&#8211;Off Therapy Registry Group, Maura Massimino, Silvia Caruso, Monica Muraca, Vera Morsellino, Claudia Casella, Lucia Miligi, Anita Andreano, Andrea Biondi, and the Italian Association of Cancer Registries Working Group; <italic toggle="yes">Netherlands:</italic> Dutch Childhood Oncology Group LATER, Wim Tissing, Marry van den Heuvel&#8208;Eibrink, Eline van Dulmen, Dorine Bresters, and Birgitta Versluys; <italic toggle="yes">Slovenia:</italic> Tina &#381;agar; <italic toggle="yes">Sweden:</italic> Ingemar Andersson and Susanne Nordenfelt; <italic toggle="yes">Switzerland:</italic> Elisabeth Kiraly, Vera Mitter, Shelagh Redmond, and the Swiss Pediatric Oncology Group (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.spog.ch/" ext-link-type="uri">www.spog.ch</ext-link>); <italic toggle="yes">United Kingdom:</italic> Julie Kelly. Author Isabelle M. Dudley also thanks the Arthur Thomson Trust at the University of Birmingham for their financial support and interest in this project. The PanCareSurFup consortium and related work was supported by the European Union&#8217;s Seventh Framework Programme for research, technological development, and demonstration under grant agreement no. 257505. Additional financial support was received from: the Foundation Force de Recherche sur le Cancer de l&#8217;Enfant, The Italian Association for Cancer Research and the Compagnia San Paolo, the Fondo Chiara Rama ONLUS, the Swedish Childhood Cancer Fund, the French Association for Cancer Research, the French National Agency for Research (Hope&#8208;Epi project), the French National Cancer Institute, Pfizer Foundation for Children and Adolescent Health, the Slovenian Research Agency, the Swiss Paediatric Oncology Group, the Swiss Cancer League (KLS&#8208;3412&#8208;02&#8208;2014, KLS&#8208;3886&#8208;02&#8208;2016, and KLS&#8208;5432&#8208;08&#8208;2021), the Swiss Cancer Research Foundation (KFS&#8208;02783&#8208;02&#8208;2011, KFS&#8208;4157&#8208;02&#8208;2017, KLA/KFS&#8208;4825&#8208;01&#8208;2019, KFS&#8208;4722&#8208;02&#8208;2019, and KFS&#8208;5302&#8208;02&#8208;2021), the Swiss National Science Foundation (PDFMP3_141775), the Dutch Cancer Society (DCOG2011&#8208;5027 and UVA2012&#8208;5517), the Norwegian Childhood Cancer Foundation, and Children with Cancer UK (grant no: 20457).</p></ack><sec sec-type="data-availability" id="cncr34561-sec-0220"><title>DATA AVAILABILITY STATEMENT</title><p>Access to anonymized data may be granted under conditions agreed with the relevant (local) legal and research ethics committees and with appropriate data sharing agreements and permissions from each data provider in place. Any data sharing would have to comply with the EU General Data Protection Regulation. The data that support the findings of this study are not publicly available because of privacy and ethical restrictions. Aggregated data in the form of tables may be available on reasonable request.</p></sec><ref-list content-type="cited-references" id="cncr34561-bibl-0001"><title>REFERENCES</title><ref id="cncr34561-bib-0001"><label>1</label><mixed-citation publication-type="miscellaneous" id="cncr34561-cit-0001"><collab collab-type="authors">Childhood Cancer International Europe</collab>
. <article-title>CCI Europe [organization website]</article-title>. Accessed August 26, 2022. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://ccieurope.eu/" ext-link-type="uri">https://ccieurope.eu/</ext-link></mixed-citation></ref><ref id="cncr34561-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="cncr34561-cit-0002"><string-name name-style="western"><surname>Steliarova&#8208;Foucher</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Stiller</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Kaatsch</surname><given-names>P</given-names></string-name>, et&#160;al. <article-title>Geographical patterns and time trends of cancer incidence and survival among children and adolescents in Europe since the 1970s (the ACCISproject): an epidemiological study</article-title>. <source>Lancet</source>. <year>2004</year>;<volume>364</volume>(<issue>9451</issue>):<fpage>2097</fpage>&#8208;<lpage>2105</lpage>. doi:<pub-id pub-id-type="doi">10.1016/s0140-6736(04)17550-8</pub-id><pub-id pub-id-type="pmid">15589307</pub-id></mixed-citation></ref><ref id="cncr34561-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="cncr34561-cit-0003"><string-name name-style="western"><surname>Gatta</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Botta</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Rossi</surname><given-names>S</given-names></string-name>, et&#160;al. <article-title>Childhood cancer survival in Europe 1999&#8211;2007: results of EUROCARE&#8208;5&#8212;a population&#8208;based study</article-title>. <source>Lancet Oncol</source>. <year>2014</year>;<volume>15</volume>(<issue>1</issue>):<fpage>35</fpage>&#8208;<lpage>47</lpage>. doi:<pub-id pub-id-type="doi">10.1016/s1470-2045(13)70548-5</pub-id><pub-id pub-id-type="pmid">24314616</pub-id></mixed-citation></ref><ref id="cncr34561-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="cncr34561-cit-0004"><string-name name-style="western"><surname>Oeffinger</surname><given-names>KC</given-names></string-name>, <string-name name-style="western"><surname>Mertens</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Sklar</surname><given-names>CA</given-names></string-name>, et&#160;al. <article-title>Chronic health conditions in adult survivors of childhood cancer</article-title>. <source>N Engl J Med</source>. <year>2006</year>;<volume>355</volume>(<issue>15</issue>):<fpage>1572</fpage>&#8208;<lpage>1582</lpage>. doi:<pub-id pub-id-type="doi">10.1056/nejmsa060185</pub-id><pub-id pub-id-type="pmid">17035650</pub-id></mixed-citation></ref><ref id="cncr34561-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="cncr34561-cit-0005"><string-name name-style="western"><surname>Geenen</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Cardous&#8208;Ubbink</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Kremer</surname><given-names>LCM</given-names></string-name>, et&#160;al. <article-title>Medical assessment of adverse health outcomes in long&#8208;term survivors of childhood cancer</article-title>. <source>JAMA</source>. <year>2007</year>;<volume>297</volume>(<issue>24</issue>):<fpage>2705</fpage>&#8208;<lpage>2715</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.297.24.2705</pub-id><pub-id pub-id-type="pmid">17595271</pub-id></mixed-citation></ref><ref id="cncr34561-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="cncr34561-cit-0006"><string-name name-style="western"><surname>Reulen</surname><given-names>RC</given-names></string-name>, <string-name name-style="western"><surname>Frobisher</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Winter</surname><given-names>DL</given-names></string-name>, et&#160;al. <article-title>Long&#8208;term risks of subsequent primary neoplasms among survivors of childhood cancer</article-title>. <source>JAMA</source>. <year>2011</year>;<volume>305</volume>(<issue>22</issue>):<fpage>2311</fpage>&#8208;<lpage>2319</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2011.747</pub-id><pub-id pub-id-type="pmid">21642683</pub-id></mixed-citation></ref><ref id="cncr34561-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="cncr34561-cit-0007"><string-name name-style="western"><surname>Olsen</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>M&#246;ller</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Anderson</surname><given-names>H</given-names></string-name>, et&#160;al. <article-title>Lifelong cancer incidence in 47,697 patients treated for childhood cancer in the Nordic countries</article-title>. <source>J Natl Cancer Inst</source>. <year>2009</year>;<volume>101</volume>(<issue>11</issue>):<fpage>806</fpage>&#8208;<lpage>813</lpage>. doi:<pub-id pub-id-type="doi">10.1093/jnci/djp104</pub-id><pub-id pub-id-type="pmid">19470947</pub-id></mixed-citation></ref><ref id="cncr34561-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="cncr34561-cit-0008"><string-name name-style="western"><surname>Teepen</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>van Leeuwen</surname><given-names>FE</given-names></string-name>, <string-name name-style="western"><surname>Tissing</surname><given-names>WJ</given-names></string-name>, et&#160;al. <article-title>Long&#8208;term risk of subsequent malignant neoplasms after treatment of childhood cancer in the DCOG LATER study cohort: role of chemotherapy</article-title>. <source>J Clin Oncol</source>. <year>2017</year>;<volume>35</volume>(<issue>20</issue>):<fpage>2288</fpage>&#8208;<lpage>2298</lpage>. doi:<pub-id pub-id-type="doi">10.1200/jco.2016.71.6902</pub-id><pub-id pub-id-type="pmid">28530852</pub-id></mixed-citation></ref><ref id="cncr34561-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="cncr34561-cit-0009"><string-name name-style="western"><surname>MacArthur</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Spinelli</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Rogers</surname><given-names>PC</given-names></string-name>, <string-name name-style="western"><surname>Goddard</surname><given-names>KJ</given-names></string-name>, <string-name name-style="western"><surname>Phillips</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>McBride</surname><given-names>ML</given-names></string-name>. <article-title>Risk of a second malignant neoplasm among 5&#8208;year survivors of cancer in childhood and adolescence in British Columbia, Canada</article-title>. <source>Pediatr Blood Cancer</source>. <year>2007</year>;<volume>48</volume>(<issue>4</issue>):<fpage>453</fpage>&#8208;<lpage>459</lpage>. doi:<pub-id pub-id-type="doi">10.1002/pbc.20921</pub-id><pub-id pub-id-type="pmid">16767718</pub-id></mixed-citation></ref><ref id="cncr34561-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="cncr34561-cit-0010"><string-name name-style="western"><surname>Turcotte</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Yasui</surname><given-names>Y</given-names></string-name>, et&#160;al. <article-title>Temporal trends in treatment and subsequent neoplasm risk among 5&#8208;year survivors of childhood cancer, 1970&#8211;2015</article-title>. <source>JAMA</source>. <year>2017</year>;<volume>317</volume>(<issue>8</issue>):<fpage>814</fpage>&#8208;<lpage>824</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2017.0693</pub-id><pub-id pub-id-type="pmid">28245323</pub-id><pub-id pub-id-type="pmcid">PMC5473951</pub-id></mixed-citation></ref><ref id="cncr34561-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="cncr34561-cit-0011"><string-name name-style="western"><surname>Turcotte</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Whitton</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Friedman</surname><given-names>DL</given-names></string-name>, et&#160;al. <article-title>Risk of subsequent neoplasms during the fifth and sixth decades of life in the Childhood Cancer Survivor Study cohort</article-title>. <source>J Clin Oncol</source>. <year>2015</year>;<volume>33</volume>(<issue>31</issue>):<fpage>3568</fpage>&#8208;<lpage>3575</lpage>. doi:<pub-id pub-id-type="doi">10.1200/jco.2015.60.9487</pub-id><pub-id pub-id-type="pmid">26261260</pub-id><pub-id pub-id-type="pmcid">PMC4622098</pub-id></mixed-citation></ref><ref id="cncr34561-bib-0012"><label>12</label><mixed-citation publication-type="book" id="cncr34561-cit-0012"><string-name name-style="western"><surname>Hodgson</surname><given-names>DC</given-names></string-name>, <string-name name-style="western"><surname>van Leeuwen</surname><given-names>FE</given-names></string-name>. <part-title>Second malignancy risk after treatment of Hodgkin lymphoma</part-title>. In: <person-group person-group-type="editor"><string-name name-style="western"><surname>Engert</surname><given-names>A</given-names></string-name></person-group>, <person-group person-group-type="editor"><string-name name-style="western"><surname>Younes</surname><given-names>A</given-names></string-name></person-group>, eds. <source>Hodgkin Lymphoma: A Comprehensive Overview [Internet]</source>. <publisher-name>Springer International Publishing</publisher-name>; <year>2015</year>:<fpage>375</fpage>&#8208;<lpage>409</lpage>. Accessed August 26, 2022. doi:<pub-id pub-id-type="doi">10.1007/978-3-319-12505-3_24</pub-id></mixed-citation></ref><ref id="cncr34561-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="cncr34561-cit-0013"><string-name name-style="western"><surname>Tucker</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Coleman</surname><given-names>CN</given-names></string-name>, <string-name name-style="western"><surname>Cox</surname><given-names>RS</given-names></string-name>, <string-name name-style="western"><surname>Varghese</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Rosenberg</surname><given-names>SA</given-names></string-name>. <article-title>Risk of second cancers after treatment for Hodgkin&#8217;s disease</article-title>. <source>N Engl J Med</source>. <year>1988</year>;<volume>318</volume>(<issue>2</issue>):<fpage>76</fpage>&#8208;<lpage>81</lpage>. doi:<pub-id pub-id-type="doi">10.1056/nejm198801143180203</pub-id><pub-id pub-id-type="pmid">3336397</pub-id></mixed-citation></ref><ref id="cncr34561-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="cncr34561-cit-0014"><string-name name-style="western"><surname>Dores</surname><given-names>GM</given-names></string-name>, <string-name name-style="western"><surname>Metayer</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Curtis</surname><given-names>RE</given-names></string-name>, et&#160;al. <article-title>Second malignant neoplasms among long&#8208;term survivors of Hodgkin&#8217;s disease: a population&#8208;based evaluation over 25 years</article-title>. <source>J Clin Oncol</source>. <year>2002</year>;<volume>20</volume>(<issue>16</issue>):<fpage>3484</fpage>&#8208;<lpage>3494</lpage>. doi:<pub-id pub-id-type="doi">10.1200/jco.2002.09.038</pub-id><pub-id pub-id-type="pmid">12177110</pub-id></mixed-citation></ref><ref id="cncr34561-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="cncr34561-cit-0015"><string-name name-style="western"><surname>Swerdlow</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Barber</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Hudson</surname><given-names>GV</given-names></string-name>, et&#160;al. <article-title>Risk of second malignancy after Hodgkin&#8217;s disease in a collaborative British cohort: the relation to age at treatment</article-title>. <source>J Clin Oncol</source>. <year>2000</year>;<volume>18</volume>(<issue>3</issue>):<fpage>498</fpage>&#8208;<lpage>509</lpage>. doi:<pub-id pub-id-type="doi">10.1200/jco.2000.18.3.498</pub-id><pub-id pub-id-type="pmid">10653865</pub-id></mixed-citation></ref><ref id="cncr34561-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="cncr34561-cit-0016"><string-name name-style="western"><surname>Swerdlow</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Higgins</surname><given-names>CD</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>P</given-names></string-name>, et&#160;al. <article-title>Second cancer risk after chemotherapy for Hodgkin&#8217;s lymphoma: a collaborative British cohort study</article-title>. <source>J Clin Oncol</source>. <year>2011</year>;<volume>29</volume>(<issue>31</issue>):<fpage>4096</fpage>&#8208;<lpage>4104</lpage>. doi:<pub-id pub-id-type="doi">10.1200/jco.2011.34.8268</pub-id><pub-id pub-id-type="pmid">21969511</pub-id></mixed-citation></ref><ref id="cncr34561-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="cncr34561-cit-0017"><string-name name-style="western"><surname>Henry&#8208;Amar</surname><given-names>M</given-names></string-name>. <article-title>Second cancer after the treatment for Hodgkin&#8217;s disease: a report from the International Database on Hodgkin&#8217;s Disease</article-title>. <source>Ann Oncol</source>. <year>1992</year>;<volume>3</volume>(<issue>suppl 4</issue>):<fpage>117</fpage>&#8208;<lpage>128</lpage>. doi:<pub-id pub-id-type="doi">10.1093/annonc/3.suppl_4.s117</pub-id><pub-id pub-id-type="pmid">1450072</pub-id></mixed-citation></ref><ref id="cncr34561-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="cncr34561-cit-0018"><string-name name-style="western"><surname>Krikorian</surname><given-names>JG</given-names></string-name>, <string-name name-style="western"><surname>Burke</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Rosenberg</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Kaplan</surname><given-names>HS</given-names></string-name>. <article-title>Occurrence of non&#8208;Hodgkin&#8217;s lymphoma after therapy for Hodgkin&#8217;s disease</article-title>. <source>N&#160;Engl J Med</source>. <year>1979</year>;<volume>300</volume>(<issue>9</issue>):<fpage>452</fpage>&#8208;<lpage>458</lpage>. doi:<pub-id pub-id-type="doi">10.1056/nejm197903013000902</pub-id><pub-id pub-id-type="pmid">366418</pub-id></mixed-citation></ref><ref id="cncr34561-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="cncr34561-cit-0019"><string-name name-style="western"><surname>Rueffer</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Josting</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Franklin</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>Non&#8208;Hodgkin&#8217;s lymphoma after primary Hodgkin&#8217;s disease in the German Hodgkin&#8217;s Lymphoma Study Group: incidence, treatment, and prognosis</article-title>. <source>J Clin Oncol</source>. <year>2001</year>;<volume>19</volume>(<issue>7</issue>):<fpage>2026</fpage>&#8208;<lpage>2032</lpage>. doi:<pub-id pub-id-type="doi">10.1200/jco.2001.19.7.2026</pub-id><pub-id pub-id-type="pmid">11310450</pub-id></mixed-citation></ref><ref id="cncr34561-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="cncr34561-cit-0020"><string-name name-style="western"><surname>van Leeuwen</surname><given-names>FE</given-names></string-name>, <string-name name-style="western"><surname>Klokman</surname><given-names>WJ</given-names></string-name>, <string-name name-style="western"><surname>Hagenbeek</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>Second cancer risk following Hodgkin&#8217;s disease: a 20&#8208;year follow&#8208;up study</article-title>. <source>J Clin Oncol</source>. <year>1994</year>;<volume>12</volume>(<issue>2</issue>):<fpage>312</fpage>&#8208;<lpage>325</lpage>. doi:<pub-id pub-id-type="doi">10.1200/jco.1994.12.2.312</pub-id><pub-id pub-id-type="pmid">8113838</pub-id></mixed-citation></ref><ref id="cncr34561-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="cncr34561-cit-0021"><string-name name-style="western"><surname>Swerdlow</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Douglas</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Hudson</surname><given-names>GV</given-names></string-name>, <string-name name-style="western"><surname>Hudson</surname><given-names>BV</given-names></string-name>, <string-name name-style="western"><surname>Bennett</surname><given-names>MH</given-names></string-name>, <string-name name-style="western"><surname>MacLennan</surname><given-names>KA</given-names></string-name>. <article-title>Risk of second primary cancers after Hodgkin&#8217;s disease by type of treatment: analysis of 2846 patients in the British&#160;National Lymphoma Investigation</article-title>. <source>BMJ</source>. <year>1992</year>;<volume>304</volume>(<issue>6835</issue>):<fpage>1137</fpage>&#8208;<lpage>1143</lpage>. doi:<pub-id pub-id-type="doi">10.1136/bmj.304.6835.1137</pub-id><pub-id pub-id-type="pmid">1392790</pub-id><pub-id pub-id-type="pmcid">PMC1882078</pub-id></mixed-citation></ref><ref id="cncr34561-bib-0022"><label>22</label><mixed-citation publication-type="miscellaneous" id="cncr34561-cit-0022"><collab collab-type="authors">PanCare [organization website]</collab>
. Accessed August 26, 2022. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pancare.eu/" ext-link-type="uri">https://www.pancare.eu/</ext-link></mixed-citation></ref><ref id="cncr34561-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="cncr34561-cit-0023"><string-name name-style="western"><surname>Hjorth</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Haupt</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Skinner</surname><given-names>R</given-names></string-name>, et&#160;al. <article-title>Survivorship after childhood cancer: PanCare: a European network to promote optimal long&#8208;term care</article-title>. <source>Eur J Cancer</source>. <year>2015</year>;<volume>51</volume>(<issue>10</issue>):<fpage>1203</fpage>&#8208;<lpage>1211</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ejca.2015.04.002</pub-id><pub-id pub-id-type="pmid">25958037</pub-id><pub-id pub-id-type="pmcid">PMC5916870</pub-id></mixed-citation></ref><ref id="cncr34561-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="cncr34561-cit-0024"><string-name name-style="western"><surname>Grabow</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Kaiser</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hjorth</surname><given-names>L</given-names></string-name>, et&#160;al. <article-title>The PanCareSurFup cohort of 83,333 five&#8208;year survivors of childhood cancer: a cohort from 12 European countries</article-title>. <source>Eur J Epidemiol</source>. <year>2018</year>;<volume>33</volume>(<issue>3</issue>):<fpage>335</fpage>&#8208;<lpage>349</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10654-018-0370-3</pub-id><pub-id pub-id-type="pmid">29497894</pub-id><pub-id pub-id-type="pmcid">PMC5889790</pub-id></mixed-citation></ref><ref id="cncr34561-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="cncr34561-cit-0025"><string-name name-style="western"><surname>Byrne</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Alessi</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Allodji</surname><given-names>RS</given-names></string-name>, et&#160;al. <article-title>The PanCareSurFup consortium: research and guidelines to improve lives for survivors of childhood cancer</article-title>. <source>Eur J Cancer</source>. <year>2018</year>;<volume>103</volume>:<fpage>238</fpage>&#8208;<lpage>248</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ejca.2018.08.017</pub-id><pub-id pub-id-type="pmid">30286417</pub-id></mixed-citation></ref><ref id="cncr34561-bib-0026"><label>26</label><mixed-citation publication-type="miscellaneous" id="cncr34561-cit-0026"><part-title>Check and conversion programs for cancer registries (</part-title><collab collab-type="authors">ARC/IARC Tools for Cancer Registries)</collab>
. <source>IARC Technical Report No. 42</source>. International Agency for Research on Cancer; <year>2005</year>.</mixed-citation></ref><ref id="cncr34561-bib-0027"><label>27</label><mixed-citation publication-type="book" id="cncr34561-cit-0027"><collab collab-type="authors">World Health Organization</collab>
. <source>International Classification of Diseases for Oncology (ICD&#8208;O) [Internet]</source>. <publisher-name>World Health Organization</publisher-name>; <year>2013</year>. Accessed August 26, 2022. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://apps.who.int/iris/handle/10665/96612" ext-link-type="uri">https://apps.who.int/iris/handle/10665/96612</ext-link></mixed-citation></ref><ref id="cncr34561-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="cncr34561-cit-0028"><string-name name-style="western"><surname>Steliarova&#8208;Foucher</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Stiller</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Lacour</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Kaatsch</surname><given-names>P</given-names></string-name>. <article-title>International Classification of Childhood Cancer, third edition</article-title>. <source>Cancer</source>. <year>2005</year>;<volume>103</volume>(<issue>7</issue>):<fpage>1457</fpage>&#8208;<lpage>1467</lpage>. doi:<pub-id pub-id-type="doi">10.1002/cncr.20910</pub-id><pub-id pub-id-type="pmid">15712273</pub-id></mixed-citation></ref><ref id="cncr34561-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="cncr34561-cit-0029"><string-name name-style="western"><surname>Breslow</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Day</surname><given-names>N</given-names></string-name>. <article-title>Statistical methods in cancer research. Volume II&#8212;The design and analysis of cohort studies</article-title>. <source>IARC Sci Publ</source>. <year>1987</year>;<volume>82</volume>:<fpage>1</fpage>&#8208;<lpage>406</lpage>.<pub-id pub-id-type="pmid">3329634</pub-id></mixed-citation></ref><ref id="cncr34561-bib-0030"><label>30</label><mixed-citation publication-type="miscellaneous" id="cncr34561-cit-0030"><collab collab-type="authors">International Agency for Research on Cancer (IARC). Cancer Incidence in Five Continents (CI5)</collab>
. <article-title>IARC</article-title>; <year>2022</year>. Accessed August 26, 2022. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://ci5.iarc.fr/Default.aspx" ext-link-type="uri">https://ci5.iarc.fr/Default.aspx</ext-link></mixed-citation></ref><ref id="cncr34561-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="cncr34561-cit-0031"><string-name name-style="western"><surname>Ferlay</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Autier</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Boniol</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Heanue</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Colombet</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Boyle</surname><given-names>P</given-names></string-name>. <article-title>Estimates of the cancer incidence and mortality in Europe in 2006</article-title>. <source>Ann Oncol</source>. <year>2007</year>;<volume>18</volume>(<issue>3</issue>):<fpage>581</fpage>&#8208;<lpage>592</lpage>. doi:<pub-id pub-id-type="doi">10.1093/annonc/mdl498</pub-id><pub-id pub-id-type="pmid">17287242</pub-id></mixed-citation></ref><ref id="cncr34561-bib-0032"><label>32</label><mixed-citation publication-type="book" id="cncr34561-cit-0032"><collab collab-type="authors">StataCorp</collab>
. <source>Stata Statistical Software: Release</source>, vol. <volume>17</volume>. <publisher-name>StataCorp LLC</publisher-name>; <year>2021</year>.</mixed-citation></ref><ref id="cncr34561-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="cncr34561-cit-0033"><string-name name-style="western"><surname>Fidler&#8208;Benaoudia</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Oeffinger</surname><given-names>KC</given-names></string-name>, <string-name name-style="western"><surname>Yasui</surname><given-names>Y</given-names></string-name>, et&#160;al. <article-title>A comparison of late mortality among survivors of childhood cancer in the United States and United Kingdom</article-title>. <source>J Natl Cancer Inst</source>. <year>2021</year>;<volume>113</volume>(<issue>5</issue>):<fpage>562</fpage>&#8208;<lpage>571</lpage>. doi:<pub-id pub-id-type="doi">10.1093/jnci/djaa151</pub-id><pub-id pub-id-type="pmid">33002115</pub-id><pub-id pub-id-type="pmcid">PMC8096371</pub-id></mixed-citation></ref><ref id="cncr34561-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="cncr34561-cit-0034"><string-name name-style="western"><surname>Zarate&#8208;Osorno</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Medeiros</surname><given-names>LJ</given-names></string-name>, <string-name name-style="western"><surname>Longo</surname><given-names>DL</given-names></string-name>, <string-name name-style="western"><surname>Jaffe</surname><given-names>ES</given-names></string-name>. <article-title>Non&#8208;Hodgkin&#8217;s lymphomas arising in patients successfully treated for Hodgkin&#8217;s disease. A clinical, histologic, and immunophenotypic study of 14 cases</article-title>. <source>Am J Surg Pathol</source>. <year>1992</year>;<volume>16</volume>(<issue>9</issue>):<fpage>885</fpage>&#8208;<lpage>895</lpage>. doi:<pub-id pub-id-type="doi">10.1097/00000478-199209000-00007</pub-id><pub-id pub-id-type="pmid">1415907</pub-id></mixed-citation></ref><ref id="cncr34561-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="cncr34561-cit-0035"><string-name name-style="western"><surname>Thandra</surname><given-names>KC</given-names></string-name>, <string-name name-style="western"><surname>Barsouk</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Saginala</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Padala</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Barsouk</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Rawla</surname><given-names>P</given-names></string-name>. <article-title>Epidemiology of non&#8208;Hodgkin&#8217;s lymphoma</article-title>. <source>Med Sci (Basel)</source>. <year>2021</year>;<volume>9</volume>(<issue>1</issue>):<elocation-id>5</elocation-id>. doi:<pub-id pub-id-type="doi">10.3390/medsci9010005</pub-id><pub-id pub-id-type="pmid">33573146</pub-id><pub-id pub-id-type="pmcid">PMC7930980</pub-id></mixed-citation></ref><ref id="cncr34561-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="cncr34561-cit-0036"><string-name name-style="western"><surname>Shannon&#8208;Lowe</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Rickinson</surname><given-names>AB</given-names></string-name>, <string-name name-style="western"><surname>Bell</surname><given-names>AI</given-names></string-name>. <article-title>Epstein&#8211;Barr virus&#8208;associated lymphomas</article-title>. <source>Philos Trans R Soc Lond B Biol Sci</source>. <year>2017</year>;<volume>372</volume>(<issue>1732</issue>):<elocation-id>20160271</elocation-id>. doi:<pub-id pub-id-type="doi">10.1098/rstb.2016.0271</pub-id><pub-id pub-id-type="pmid">28893938</pub-id><pub-id pub-id-type="pmcid">PMC5597738</pub-id></mixed-citation></ref><ref id="cncr34561-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="cncr34561-cit-0037"><string-name name-style="western"><surname>Gottschalk</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Rooney</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Heslop</surname><given-names>HE</given-names></string-name>. <article-title>Post&#8208;transplant lymphoproliferative disorders</article-title>. <source>Annu Rev Med</source>. <year>2005</year>;<volume>56</volume>(<issue>1</issue>):<fpage>29</fpage>&#8208;<lpage>44</lpage>. doi:<pub-id pub-id-type="doi">10.1146/annurev.med.56.082103.104727</pub-id><pub-id pub-id-type="pmid">15660500</pub-id></mixed-citation></ref><ref id="cncr34561-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="cncr34561-cit-0038"><string-name name-style="western"><surname>Grenda</surname><given-names>R</given-names></string-name>. <article-title>Non&#8208;Hodgkin lymphoma after pediatric kidney transplantation</article-title>. <source>Pediatr Nephrol</source>. <year>2022</year>;<volume>37</volume>(<issue>8</issue>):<fpage>1759</fpage>&#8208;<lpage>1773</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00467-021-05205-6</pub-id><pub-id pub-id-type="pmid">34633534</pub-id><pub-id pub-id-type="pmcid">PMC9239945</pub-id></mixed-citation></ref><ref id="cncr34561-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="cncr34561-cit-0039"><string-name name-style="western"><surname>Hsu</surname><given-names>WL</given-names></string-name>, <string-name name-style="western"><surname>Preston</surname><given-names>DL</given-names></string-name>, <string-name name-style="western"><surname>Soda</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>The incidence of leukemia, lymphoma and multiple myeloma among atomic bomb survivors:&#160;1950&#8211;2001</article-title>. <source>Radiat Res</source>. <year>2013</year>;<volume>179</volume>(<issue>3</issue>):<fpage>361</fpage>&#8208;<lpage>382</lpage>. doi:<pub-id pub-id-type="doi">10.1667/rr2892.1</pub-id><pub-id pub-id-type="pmid">23398354</pub-id><pub-id pub-id-type="pmcid">PMC3875218</pub-id></mixed-citation></ref><ref id="cncr34561-bib-0040"><label>40</label><mixed-citation publication-type="miscellaneous" id="cncr34561-cit-0040"><collab collab-type="authors">Children&#8217;s Oncology Group (COG)</collab>
. <article-title>Long&#8208;Term Follow&#8208;Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers, version 5.0</article-title>. COG; <year>2018</year>. Accessed August 26, 2022. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.survivorshipguidelines.org/pdf/2018/COG_LTFU_Guidelines_v5.pdf" ext-link-type="uri">http://www.survivorshipguidelines.org/pdf/2018/COG_LTFU_Guidelines_v5.pdf</ext-link></mixed-citation></ref></ref-list></back></article></pmc-articleset>